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Stroke is a major cause of death and disability, incurs significant costs to healthcare 
systems, and inflicts severe burden to the whole society. There are numerous evidence-
based interventions available for treatment of stroke patients, but these are not utilized 
optimally. Information on details of stroke care in Finland has been systematically 
gathered in several population-based epidemiological studies between 1967 and 1998, but 
not since. Feedback on quality and outcome of care is vital for improving daily clinical 
practice. In the PERFECT Stroke study presented here, a system for monitoring the 
Performance, Effectiveness, and Costs of Treatment episodes in Stroke was developed in 
Finland. 
 
In this study, only first-in-a-lifetime stroke patients were included. Existing nationwide 
administrative registries were linked at individual patient level with personal identification 
numbers to depict whole episodes of care, from acute stroke, through rehabilitation, until 
the patients went home, were admitted to permanent institutional care, or died. Patient 
catchment was hospital-based, while data collection on follow-up was population-based. 
Several healthcare providers, multiple comorbidities, and need for long-term follow-up 
with secondary prevention interventions were usually involved in the care of patients, and 
all of these were evaluated from existing national databases. Data on national trends in the 
epidemiology, treatment, and outcome of stroke patients from the year 1999 to 2008 were 
gathered for the present study. For comparisons in time and between providers, patient 
case-mix was adjusted for. 
 
The PERFECT Stroke database includes 104 899 first-ever stroke patients over the years 
1999 to 2008, of whom 79.1% had ischemic stroke (IS), 13.6% intracerebral hemorrhage 
(ICH), and 7.3% subarachnoid hemorrhage (SAH) as their first-ever stroke. The median 
age was 74 years, with one in four patients being working-age, below 63 years of age. Of 
all patients, 6% were living in an institution before their first-in-a-lifetime stroke. 
 
An age and sex adjusted decrease of 18% in the incidence of stroke was observed over the 
study period, 1.8% improvement annually. All-cause 1-year case-fatality rate of stroke 
patients improved from 28.6% to 24.6%, or 0.5% annually. Accordingly, the positive 
developments observed since the 1970’s of decrease in both stroke incidence and case-
fatality rates continued during the current study period. This can be explained by 
continuing favorable developments in stroke risk factors in the population, and with 
improved care. Due to improved survival, the expected median lifetime after stroke 
increased by 2 years for IS patients, being 7 years and 7 months at the end of the study 
period, and by 1 year for ICH patients, being 4 years 5 months. No change could be seen 
in median SAH patient survival, which was more than 10 years. Increased survival has led 
to increased stroke prevalence in the population, estimated to be 82 000 people, 1.5% of 






In this study, for the first time, modern stroke center care was shown to be effective at 
population level covering the whole nation, with significant decrease in both death and 
risk of institutional care in patients treated in stroke centers, number needed to treat to 
prevent these poor outcomes at one year from stroke 32; 95% confidence intervals 26 to 
42.  
 
Despite improvements over the study period, more than a third of Finnish stroke patients 
did not have access to this evidence-based stroke center care, and half of survivors did not 
receive secondary preventive medications as recommended in national guidelines. There is 
a pressing need to improve these clinical practices. Monitoring for such developments 
together with public awareness of the issues will hopefully promote change.  
 
The mean direct healthcare cost of a stroke patient was shown to be about 20 000 € over 
the first year after stroke, and about 10 000 € annually thereafter for survivors. Only part 
of these costs were incurred by the stroke, as the healthcare of the same patients cost about 
5000 € over the one year immediately before their initial stroke. The total costs of a stroke 
patient were estimated to be about 85 000 € over their remaining lifetime after their first-
ever stroke. With the increased prevalence of stroke in the society, already 7% of all 
healthcare costs are used in the treatment of stroke patients, i.e. 1.1 Billion € annually. 
 
Most of the results in this study are only applicable in Finland. For the international 
audience, there are two messages. 1) Stroke center care is effective, and should be made 
available for all stroke patients. 2) It is possible, in a suitable setting with high-quality 
administrative registries and a common identifier, to avoid the huge workload and 
associated costs of setting up a conventional stroke registry, and still be able to acquire a 






Sometimes blood does not flow in the brain as it should do. It either stops; leaving neurons 
deprived of oxygen and glucose, or breaks outside of its vessels; tearing the soft brain 
tissue with force and pressure. In these situations, part of the brain dies, and we see a 
clinical syndrome known as a stroke. 
 
As much as understanding on the mechanisms involved in these disturbances of blood 
flow has been gained, there is still scarce little we can do. Mostly, nature takes its course 
and eventually repairs part of the damage. We can try to clear the blockage in the flow, but 
in  only few percentages of ischemic stroke patients this is attempted; and re-canalization 
of the occluded vessel succeeds in only half of these. In bleeds, a majority of the damage 
is done immediately. Thus, acute stroke care is mainly about helping the nature, giving the 
damaged brain an optimal environment to heal. We try to normalize and optimize brain 
physiology, although we know little of what would be optimal here. Irrespective of our 
attempts, eventually balance will be restored, dead tissue will be cleared away, and viable 
tissue will take over some of the lost functions. Lying in a bed, immobile, incapacitated, 
and under stress, is a state unnatural for the whole human body, leading to problems also 
outside of the brain. Many of them can be looked for, treated, and prevented. The factors 
that have caused the blood flow disruption, such as hypertension or arterial stenosis, 
usually do not go away by themselves, and often produce new attacks. To prevent this, 
several effective interventions are available. Helping the body to heal after stroke includes 
several concurrent and intertwined processes, best accomplished by a team of experts 
equipped with the appropriate tools and facilities. These things are what stroke care is all 
about. 
 
It is only natural that professionals think they are good in their clinical work. However, 
this is not always true, and simple easily corrected issues can cause suboptimal results and 
even major complications. Medicine evolves, and not everybody is able to keep track 
while busy with the daily workload. National guidelines help, but are not always followed. 
Thus, quality needs to be measured; in order to pinpoint areas where practice fails to meet 
targets. 
 
In the PERFECT Stroke study, an attempt has been made to measure the process of care of 
stroke patients in Finland, to depict the burden this disease inflicts on the society, to see 






2 REVIEW OF THE LITERATURE 
2.1 Definition of Stroke 
Voltaire (1694-1778) said: “If you wish to converse with me, define your terms.” Even 
today, among experts, the definition of the term stroke is far from uniform. 
2.1.1 The WHO definition 
Finland has a long tradition in the epidemiological research on stroke, and Finnish stroke 
experts have contributed to the most widely used definition of the disease over the last 40 
years, the World Health Organization (WHO) definition.  
 
The classical WHO definition of stroke was introduced with the WHO Collaborative 
Study on Cerebrovascular Disease in the Community. This first multinational 
epidemiological study on stroke was suggested in a WHO meeting in Monaco in 1970, 
where 51 stroke experts convened, among them two colleagues from our own institute, 
Rainer Fogelholm and Seppo Pakarinen. The meeting suggested a simple definition for 
stroke;  
 
“A sudden onset of disturbance of focal brain function due to the blockage 
or rupture of blood vessels.” (WHO 1971) 
  
The details of the study were planned in 1971, and 3 of the 24 collaboration researchers 
were Finns; Kari Aho (Helsinki), Pekka Puska (Kuopio), and Kalervo Salmi (Joensuu). 
Around the same time, Pekka Puska became the primary investigator of another 
epidemiological study on cardiovascular disease, the North Karelia project, initially 
planned in a seminar in September 1971 (Puska et al. 2009). The two studies have 
benefited from each other and contributed to a strong tradition of cardiovascular 
epidemiological research in Finland. 
 
The WHO definition was originally formulated over several planning meetings, described 
in detail in three WHO internal documents not widely available: 
 
 WHO: Control of stroke and hypertension in the community, Report of a WHO meeting, 
Geneva, February 1971. Internal Document CVD/71.3, Geneva, WHO, 1971 
 WHO: Community control of stroke and hypertension. Report of a WHO meeting, 
Goteborg, November-December 1971. Internal Document CVD/72.1, Geneva, WHO, 
1972 
 WHO: Control of stroke in the community. Methodological considerations and protocol of 





As these WHO internal documents are hard to come by, an often cited reference of the 
WHO definition is the one described in the WHO Chronicles by Hatano (Hatano 1972): 
 
Stroke was regarded by the meeting as being manifested by rapidly 
developing clinical signs of focal or global disturbance of cerebral function 
leading to death or lasting more than 24 hours with no apparent cause other 
than a vascular one. Thus, the term covers patients presenting clinical signs 
and symptoms suggestive of subarachnoid haemorrhage, intracerebral 
haemorrhage, or cerebral ischaemic necrosis and also some patients in deep 
coma. It does not cover those with systemic circulatory failure or 
hypertensive encephalopathy. 
The clinical diagnosis of stroke is used as the criterion for entry in the stroke 
register. Autopsied patients with fresh cerebrovascular disease who did not 
manifest clinical signs of stroke while alive are therefore not registered. 
Transient cerebral ischemia is not included, since the scrutiny of patients in 
the community is limited and there is as yet no agreement on uniform 
diagnostic procedures for this condition. Chronic brain conditions with 
mental deterioration and gradually developing neurological abnormalities 
are also excluded from the study, since a vascular origin cannot be definitely 
proved and the management of patients suffering from these conditions differ 
from that of acute stroke patients.  
 
 
Reports from the WHO Collaborative study have since quoted the definition with slight 
but not insignificant variations (underlined). 
 
First scientific report from a population of the study (Aho and Fogelholm 1974): 
 
Stroke is defined as rapidly developed clinical signs of focal (or global) 
disturbance of cerebral functions lasting more than 24 hours or leading to 
death, with no apparent cause other than a vascular origin. Included are 
subarachnoid hemorrhage, intracerebral hemorrhage and ischemic brain 
infarction, both embolic and nonembolic. Transient ischemic attacks are 
excluded according to this definition. 
 
A preliminary report of the study results is another source that is often quoted as the WHO 
definition (Hatano 1976): 
 
A stroke was defined as rapidly developing clinical signs of focal (at times 
global) disturbance of cerebral function, lasting more than 24 h or leading 
to death with no apparent cause other than that of vascular origin. The term 
“global” is applied to patients in deep coma and to those with subarachnoid 
haemorrhage. Transient episodes of cerebral ischaemia were excluded by 
definition. Cerebrovascular lesions discovered at autopsy without having 






The final report of the study again quoted a slightly different definition (Aho et al. 1980): 
 
Stroke was defined as “rapidly developed clinical signs of focal (or global) 
disturbance of cerebral function, lasting more than 24 hours or leading to 
death, with no apparent cause other than of vascular origin”. This definition 
obviously includes most cases of subarachnoid haemorrhage, intracranial 
haemorrhage, and cerebral infarction, but not cases of transient ischaemic 
attacks. The term “global” disturbances of cerebral function refers only to 
patients with subarachnoid haemorrhage without focal neurological deficits. 
 
It could therefore be argued, that the WHO definition is not quite uniform, but rather 
depends on the article quoted. In any case, the definition is a clinical one, reflecting the era 
before widespread use of computer tomography (CT) imaging of the brain. 
 
Later, in the 1970’s, the WHO provided some new definitions of cerebrovascular diseases, 
which still considered symptoms lasting less than 24 hours as TIA, but rather than define 
stroke, called symptoms lasting 1 to 21 days “reversible ischemic neurological deficit 
(RIND)”, and any symptoms lasting longer as “permanent prolonged neurological deficit 
(commonly known as “completed stroke”)” (WHO 1978) based largely on a previous US 
report (Millikan et al. 1975). In the 1980’s, the WHO provided a new definition (Goldstein 
et al. 1989): 
 
Clinically, a stroke is defined as an acute neurologic dysfunction of vascular 
origin with sudden (within seconds) or at least rapid (within hours) 
occurrence of symptoms and signs corresponding to the involvement of focal 
areas in the brain. Excluded from this definition are syncopes of cardiac or 
other origin in which no focal cerebral symptoms are present and 
uncomplicated SAH in which there is no damage to the brain itself. … If the 
symptoms and signs disappear completely within a few minutes or hours 
(<24 hours by convention), the event is termed a TIA. … Strokes can be 
divided into two broad categories according to the nature of the cerebral 
lesion: infarcts and hemorrhages. A cerebral infarct is the result of 
temporary or permanent occlusion of a feeding artery, extracranially or 
intracranially, or (more rarely) of venous thrombosis. A spontaneous 
cerebral hemorrhage is due to the rupture of an abnormal artery (aneurysm 
or AVM) or arteriole in the brain parenchyma. 
 
The revised WHO definitions have not gained much attention, and the original definition 






2.1.2 International classification of diseases (ICD) definitions 
Classification of diseases in Finland has been based on the WHO international 
classification of diseases, 8th version (ICD-8) over the years 1967-1986, 9th version (ICD-
9) over the years 1987-1995, and 10th version (ICD-10) since 1996.  
 
The classifications of 1967 and 1987 had significant national modifications. The Finnish 
ICD-9 had a fifth digit used for national purposes only. Within stroke diagnoses, the main 
difference as compared to the international version was the differentiation between 
patients with (fifth digit A) and without (X) infarction, used with the ICD-9 groups 433 
and 434 (occlusion/stenosis of cerebral/pre-cerebral arteries). The discrepancy has been 
removed with ICD-10. Many countries still use the ICD-9. There are some differences in 
the logic of ICD-9 and ICD-10; with ischemic stroke (IS, 433-434 or I63 respectively) 
being classified into etiological subtypes differently in the two versions; ischemic stroke 
including venous thrombosis in ICD-10 (I63.6), but not ICD-9 (4376); and finally 
intracerebral hemorrhage (ICH, 431 or I63) and subarachnoid hemorrhage (SAH, 430 or 
I60) being subdivided by location in ICD-10, but not ICD-9. 
2.1.3 Gray areas in the definitions 
There are several cerebrovascular disorders on the border zone of the stroke definition, 
included in stroke by some, but no by others: 
 
Subarachnoid hemorrhage (SAH) 
From the WHO definition it is clear that SAH is considered a stroke, although many 
studies on stroke have excluded these patients, and rather included only ischemic stroke 
and primary intracerebral hemorrhages. SAH without damage to the brain is especially 
difficult to clearly include or exclude in stroke, as the existence or non-existence of brain 
damage is difficult to prove.  
 
Epidural and subdural hematomas 
Epidural and subdural hematomas are usually never considered a stroke when due to a 
trauma (ICD-10 codes S06.4 and S06.5), then being of traumatic origin, rather than of 
vascular origin. Epidural and subdural hematomas may develop without a known trauma, 
and are then coded as I62 in the ICD-10 system. Some epidemiological studies using ICD-
classification have included these in the definition of stroke, while most experts would not 
consider subdural hematoma as ”vascular cause” (Albers et al. 2002). 
 
Traumatic ICH and SAH 
Like traumatic epidural and subdural hematomas, trauma can also produce ICH or SAH 
(ICD-10 diagnoses S06.3 and S06.6 respectively). These are not usually considered stroke, 
although missing patient history may sometimes make it difficult to clinically differentiate 







Cerebral venous thrombosis (CVT)  
CVT without brain damage should not be a stroke according to any definition, and is not 
considered one in the new ICD-10 classification (I67.6) Many stroke studies have 
excluded CVT also when it causes an infarct (ICD-10; I63.6) or a hemorrhage (no distinct 
ICD-10 code, included in I61), a legacy of the ICD-9 coding logic.   
 
Hypoxic-ischemic encephalopathy 
Global ischemia of the brain, as in cardiac arrest, is not considered stroke in the WHO 
definition (Hatano 1972), but some literature does count this as a special case of stroke. 
 
Recanalization of ischemic stroke, and surgery of ICH 
There is some discrepancy in coding of strokes when symptoms are reversed with therapy, 
such as thrombolytic therapy or mechanical thrombectomy in ischemic stroke, or surgery 
in hemorrhagic stroke. 
 
Retinal ischemia 
While transient blindness due to ischemia of the retina, i.e. amaurosis fugax, is in the ICD-
10 classification considered within TIA (G45.3), permanent ischemia of the retina, ”retinal 
stroke”, is not classified within the stroke diagnoses (H34).  
 
Ill-defined stroke 
Patients with a clinical picture of stroke and no imaging available are often diagnosed as 
ill-defined or undetermined stroke. While purely clinical diagnosis of stroke is quite 
acceptable according to the WHO definition, in developed countries imaging is currently 
standard practice, perhaps omitted only in some elderly patients with a very poor 
prognosis. A review of the literature showed that with purely clinical diagnosis, 21% of 
patients considered as having a stroke truly have a different condition, and thus are given 
an incorrect stroke diagnosis. In addition, 14% of strokes are misdiagnosed as another 
condition, whereby the stroke is missed. Therefore no reliable distinction between 
ischemic and hemorrhagic stroke can be made purely on clinical grounds (Goldstein and 
Simel 2005).  
2.1.4 New tissue-based definitions 
With clear imaging and cerebrospinal fluid (CSF) findings, although subject to some error, 
the diagnoses of ICH (Qureshi et al. 2009; Cordonnier et al. 2010) and SAH (van Gijn et 
al. 2007) are rather straightforward. However, with ischemic stroke, the diagnosis has 
been traditionally more clinical, often with no imaging findings if imaged early and with 
CT technology. With better understanding of the disease mechanisms, and new imaging 
possibilities, proposals for revised diagnostic criteria for ischemic stroke have been put 





WHO definition at 24-hours of symptom duration, has been questioned with new tissue-
based diagnostic criteria: 
 
A TIA is a brief episode of neurologic dysfunction caused by focal brain or 
retinal ischemia, with clinical symptoms typically lasting less than one hour, 
and without evidence of acute infarction. (Albers et al. 2002). 
 
In the future, the definition of stroke will remain a clinical one, but imaging will be 
compulsory to rule out other explanations for the symptoms, and, in the case of resolved 
symptoms, to visualize subclinical stroke. 
 
Definition of stroke 
Summary points 
 
1. Finnish physicians were involved in formulating the classic WHO definition of stroke 
in the 1970’s. 
2. The definitions are not quite uniform and may or may not include certain types of 
cerebrovascular diseases. 
3. Although the definitions do not clearly state this, it has been customary to consider 
stroke as cerebral infarction, intracerebral hemorrhage, and subarachnoid hemorrhage, 
due to arterial or venous causes, and exclude TIA, hypoxic-ischemic encephalopathy, 
traumatic hemorrhages, and non-traumatic epidural and subdural hemorrhages. 
4. Stroke diagnostic criteria have changed with enhanced imaging and better 
understanding of pathology. This will lead to increase in total stroke cases, as more 








2.2 Incidence of Stroke 
Incidence is the number of new (first-in-a-lifetime) stroke cases in a certain population 
and within a given period, usually one year. Incidence is often expressed as cases per 
1000, 10 000, or 100 000 persons at risk, either in the whole population, in a certain age- 
and/or sex- group, or in an adjusted population. Adjusted populations are used to make 
incidence figures comparable in time or across populations. Several standard adjusted 
populations (Europe, World) exist for international comparison, while national 
comparisons are usually performed to a population of a fixed year.  
 
International standards for stroke incidence studies have been suggested by Sudlow and 
Warlow (Sudlow and Warlow 1996). They suggest that hospital-based populations never 
represent the whole community, as a significant proportion of patients are not admitted to 
a hospital. Suggested reasons for not admitting are: death before admission; no perceived 
advantage due to old age, previous disability, too severe, or too mild stroke; too remote, 
expensive, not available, or full hospital. Population-based incidence studies with multiple 
overlapping case finding strategies are the golden standard of stroke incidence. 
2.2.1 Worldwide incidence of stroke 
The worldwide annual stroke incidence has been estimated at 9.0 million in the year 2004, 
of which 2.0 million occur in Europe (WHO 2008), and 0.6 in the USA (Roger et al. 
2010). A recent systematic review on stroke incidence identified 56 population-based 
studies performed in 47 centers and 28 countries over the years 1970 to 2006 (Feigin et al. 
2009). Only 12 countries have population-based data on time-trends in stroke incidence, 
namely Australia, Denmark, Estonia, Finland, France, Italy, Japan, New Zealand, Russia, 
Sweden, UK, and USA. The review revealed several worldwide trends: 
 
 There has been huge differences in reported crude stroke incidence rates, ranging 
from 15 (Ibadan, Nigeria, years 1971-74) to 483 (Turku, Finland, year 1987) per 
100 000 population. 
 Age-standardized stroke incidence rates have declined by 42% since the 1970’s in 
high-income countries (-1% annually), but increased by 125% in low to middle 
income countries (+5% annually). 
 The same global trends in incidence can be seen in both young and elderly 
patients. 
 In high-income countries, the reduction in incidence is more due to reduction in 
ICH than IS incidence, while there has been no change in SAH incidence. 
 After adjusting for age, ischemic stroke is as common in high-income and low to 
middle income countries, but hemorrhagic stroke is twice as common in the low to 






A separate systematic review has been performed for incidence of ICH (van Asch et al. 
2010). This review did not analyze countries according to income, and while showing a 
3% annual decrease in crude incidence of ICH, observed no change in age- and sex 
adjusted incidence among the studies with highest quality case-finding standards. Asian 
ethnicity was associated with two-fold incidence of ICH, and age was the strongest driver 
of incidence, with a ten-fold incidence among those aged 85+ when compared to the 50-
year olds. 
 
There is significant geographical variation as to stroke subtypes in the total stroke 
incidence. In addition to Asian race, also low-income countries tend to have a higher 
proportion of hemorrhagic strokes, possibly due to poor control of hypertension (Feigin et 
al. 2009). In the USA, 10% of all strokes are ICH, and 3% SAH (Roger et al. 2010), while 
in Japan the proportion of hemorrhagic strokes has been 20 to 30% (Kubo et al. 2003; 
Yokota et al. 2004), and even higher rates of 36% have been reported in Georgia 
(Tsiskaridze et al. 2004). 
2.2.2 Incidence of stroke in Finland 
Incidence of stroke in Finland has been studied in the academic dissertations of Seppo 
Pakarinen (Pakarinen 1967), Kari Aho (Aho 1975), Juhani Sivenius (Sivenius 1982), 
Mervi Kotila (Kotila 1986), Aimo Rissanen (Rissanen 1992), and Cinzia Sarti (Sarti 
1994), and several other studies. 
 
Helsinki subarachnoid hemorrhage study 1952-1961 
Incidence of subarachnoid hemorrhage was studied by Seppo Pakarinen in the Helsinki 
area over the years 1952 to 1961. The study patients were hand-searched from the death 
certificates and hospital records of all hospitals in the Helsinki area. Altogether, 589 
patients with primary subarachnoid hemorrhage were found, and 554 of these were 
incident cases. Crude incidence was 16 per 100 000 population (Pakarinen 1967). This 
study was the first population-based incidence study of SAH. 
 
SII Mobile Clinic Health Examination Survey 1966-1976 
The Social Insurance Institute Mobile Clinic Health Examination Survey (Reunanen et al. 
1983; Reunanen et al. 1986) was a cohort follow-up study, with 12 cohorts of population 
aged above 15 years, distributed throughout Finland, recruited between 1966 – 1972, and 
a follow-up of mean 6 years, up to 1976. Several diseases were studied. Participation rate 
was 83% (n=24,747), and only 5% were lost to follow-up. In addition to clinical and 
questionnaire follow-up, the study used multiple registries to identify stroke incidence 
(death certificates, hospital discharge registries, invalidity pensions, and fully reimbursed 
chronic conditions). A total of 310 incident stroke cases were registered, and the crude 
annual incidence was 340 per 100 000 population, dropping to 275 annually if only 






autopsy was performed in only 19%. In half of the stroke patients, the stroke subtype 
could not be defined. 
 
WHO Collaborative Study on Cerebrovascular disease in the community 1972-1974 
and follow-up studies in the same regions  
The first population-based incidence studies in Finland studying all stroke subtypes were 
conducted as part of the WHO collaboration in the areas of Espoo-Kauniainen and North 
Karelia. The Espoo-Kauniainen study started rapidly after the WHO planning meeting 
held in October 1971. The first announcement of the study was made in the Finnish 
Medical Journal in December 1971 (Aho et al. 1971), and the study ran for two years from 
January 1972 to December 1973. The detailed data on these patients were presented in the 
academic dissertation of Kari Aho (Aho 1975), and some further details of the same 
patients were presented in the dissertation of Mervi Kotila (Kotila 1986) and a later meta-
analysis by Heikki Numminen and colleagues (Numminen et al. 1996). A total of 286 
patients were included in the registry with multiple overlapping sources and hot pursuit of 
cases. Of these patients, 244 were first first-in-a-lifetime strokes while 42 (15%) had a 
history of stroke prior to 1972. The stroke subtypes were ischemic (61%), ICH (16%), 
SAH (15%), and undetermined (7%). Median age was 66 years, with a range from 24 to 
93 years. In the very young population of the recently urbanized area, when only first-ever 
strokes were counted, the crude annual stroke incidence was 108 per 100 000 population. 
The results of the WHO study are summed in a preliminary report (Hatano 1976), and a 
final report (Aho et al. 1980), which confusingly report the numbers of patients in the 
Espoo-Kauniainen study to have been 299 and 303 respectively. 
 
As part of Mervi Kotila’s academic dissertation, a similar registry was kept in the same 
area for two years from April 1978 to March 1980. The methods were otherwise identical 
to those of the years 1972 to 1974, but outpatients were not searched for. In the 1972-1973 
period, 12% of the patients in Aho’s study were not admitted to a hospital (Hatano 1976). 
A total of 255 patients were included. Crude annual first-ever stroke incidence was 93 per 
100 000 population, a 26% decrease from the previous period after age- and sex-
standardization, but not statistically significant (Kotila 1984; Kotila 1986), and obviously 
partly explained by lack of outpatient pursuit. 
 
The North Karelia study arm of the WHO study started in May 1972. As part of the WHO 
study, up to December 1974, it registered 938 stroke patients, about 85% of whom were 
incident cases, and 89% were treated in hospitals. Crude annual incidence was 171 per 
100 000 population (Puska et al. 1974; Hatano 1976; Aho et al. 1980). Registration of 
stroke patients was continued in North Karelia for two decades, first as an independent 
registry, and then as part of the FINMONICA study over the years 1983 to 1992, but no 
quality control existed between 1975 and 1980, making the data for this period less 
comparable (Tuomilehto et al. 1993). 
 
The incidence results of these WHO study and follow-up studies have been presented in 





Salonen et al. 1979; Aho et al. 1980; Kotila 1984; Kotila 1986; Tuomilehto et al. 1993; 
Numminen et al. 1996). It must be noted that the Espoo-Kauniainen 1972-1973 and the 
North Karelia studies registered also patients with a history of previous stroke, and these 
recurrent cases constituted 16%  (Aho and Fogelholm 1974) and 20% of the incidence 
(Puska et al. 1974) respectively. There is some variation in the incidence reported from 
these studies, as recurrent cases are included in the incidence figures of some papers, and 
excluded from others. 
 
Jyväskylä region 1976-1978 (SAH), 1985-1989 (ICH), 1985-86 and 1993 (All stroke)  
Several studies on stroke epidemiology have been performed in the Jyväskylä region in 
Central Finland. The first project concerned SAH patients, and was run over the years 
1976-1978, but was retrospective, and included only patients from hospital and autopsy 
records, n=140 incident cases. Crude incidence was 19 per 100 000 population 
(Fogelholm 1981). Total stroke incidence was studied more thoroughly in the Jyväskylä 
region over the periods of 1985-1986 (n=219), and 1993 (n=189), for one full year in both 
instances. In addition to hospital records and death certificates, also community health 
center data was collected. A CT scan or autopsy was performed in 68% of patients in the 
first period, and 91% of patients in the second period. Crude annual incidence decreased 
from 191 to 154 per 100 000 population. After age-standardization, a 28% decline in 
incidence was reported (Fogelholm et al. 1997). A similar method was used to gather 
information on ICH incidence over the years 1985-1989, n=158, and crude annual 
incidence was 31 per 100 000 (Fogelholm et al. 1992). 
 
Kuopio region 
As part of Juhani Sivenius’s academic dissertation, a population-based stroke registry was 
kept in the Kuopio region (Kuopio, Maaninka, Siilinjärvi, Vehmersalmi) for 20 months, 
from 1st Oct 1978 to 31st May 1980, and 300 first-ever strokes were registered, together 
with 73 recurrent cases. Multiple overlapping casefinding strategies were utilized, and 40 
cases were found from death certificates only. The annual crude incidence was 235 per 
100 000 population (Sivenius 1982). 
 
FINMONICA (1982-1992) and FINSTROKE (1993-1997) studies 
The World Health Organization Monitoring Trends and Determinants in Cardiovascular 
Disease (WHO MONICA) study was an international collaboration of uniform procedures 
to register cardiovascular disease and stroke (Asplund et al. 1988; Tuomilehto et al. 1992; 
Thorvaldsen et al. 1995). The study was run at three geographical areas in Finland (North 
Karelia, Kuopio, Turku-Loimaa) over the years 1983 – 1992, and in smaller areas of 
Kuopio and Turku over the years 1993-1997, with the names FINMONICA and 
FINSTROKE (Tuomilehto et al. 1992; Sarti 1993; Sarti et al. 1993; Tuomilehto et al. 
1993; Tuomilehto et al. 1996; Immonen-Raiha et al. 1997; Tolonen et al. 2002; Immonen-
Raiha et al. 2003; Lehtonen et al. 2004; Sivenius et al. 2004; Sivenius et al. 2009). The 
population-based study only included patients aged 25-74 (n=5650). In addition, patients 
aged >74 were registered in Turku from 1982 to 1992, and again from 1996 to 1998, and 






finding strategies were used. CT, MRI, or autopsy rate approached 100% towards the end 
of the study. Even in the >75 year olds, only 2% of stroke cases were not imaged or 
autopsied, and a further 8% not imaged in the year 1997 (Lehtonen et al. 2004). Stroke 
incidence and mortality was reported to decline in Finland on average by 2.1% annually 
from 1982 to 1998 in the >74 year olds after age-standardization (Lehtonen et al. 2004), 
and by 1.9% annually from 1983 to 1997 in the <75 year olds after age-standardization 
(Sivenius et al. 2004). 
 
Finnish Heart Association study 1989-1991 
A study with the same methodology as the Espoo-Kauniainen studies was conducted over 
two year at four separate Finnish regions from August 1989 to August 1991. A total of 
594 first-ever stroke patients were registered, and the crude incidence was 220 per 
100 000 population. The study data has been published in comparison with the Espoo-
Kauniainen studies. A 20% decrease in age-adjusted incidence from 1972 to 1991 was 
reported (Numminen et al. 1996) together with an observation of decrease in stroke 
severity (Numminen et al. 2000a). 
 
CVDR 
The Finnish Cardiovascular Disease Registry is a register-based database, available at 
www.ktl.fi/cvdr, joining the national hospital discharge registry (HILMO), and the causes 
of death registry (CDR) since year 1991 (Laatikainen et al. 2004; Pajunen et al. 2005). 
Stroke incidence was calculated with the ICD-9 diagnosis codes 430-432, 4330A, 4331A, 
4339A, 4340A, 4341A, 4349A, 436, and the ICD-10 diagnosis codes I60-I64 excluding 
I63.6 (cerebral venous infarction), and thus included also non-traumatic epidural and 
subdural hematomas (I62). A stroke was considered incident when no prior stroke 
diagnoses were present for the previous 7 years. A declining trend in incidence was 
reported, over the years 1991 to 2002 and after age-standardization, to be about 2% 
annually (Pajunen et al. 2005). The total number of new annual stroke cases with this 
methodology has been 13 385 in 1991, 13 526 in 1999, and 13 374 in 2007 (Laatikainen et 
al. 2004). 
 
Incidence of stroke 
Summary points 
 
1. Age-standardized incidence of stroke has declined over the last decades in high-
income countries, especially in ICH patients, but also in IS patients. 
2. Epidemiology of stroke in Finland has been well documented in several population-
based studies over the last decades, up to year 1997, and in administrative register-
based studies since. 
3. Standardized stroke incidence has declined in Finland steadily since the 1960’s. 
4. The reduction in age-standardized incidence has counteracted the effects of the rapidly 





2.3 Risk Factors of Stroke 
Advanced age is the most important risk factor for stroke, as stroke rates double for every 
10 years of age after the age of 55 (Goldstein et al. 2011). The other non-modifiable risk 
factors are male sex, non-white race, and a family history of stroke (Seshadri et al. 2010; 
Goldstein et al. 2011). With a rapidly aging population in Finland, and no change in the 
other non-modifiable risk-factors, one would expect to see swiftly increasing numbers of 
stroke patients. This has not been the case, most likely attributable to positive 
developments in the modifiable risk factors of stroke. 
 
Primary prevention is probably the most effective intervention against the burden stroke, 
but not easy to accomplish, and could be quite costly (Kahn et al. 2008). Prevention and 
treatment of hypertension is crucial in this aspect, together with healthy diet, physical 
activity, and campaigns against smoking / excessive alcohol use (Salonen et al. 1982; 
Straus et al. 2002; Goldstein et al. 2006; Myint et al. 2009; Willey et al. 2009; Goldstein 
et al. 2011). The recent INTERSTROKE study performed in 22 countries identified 5 risk 
factors which together accounted for 80% of the population-attributable-risk for stroke, 
namely hypertension, current smoking, abdominal obesity, poor diet, and lack of physical 
activity (O'Donnell et al. 2010). These risk factors were common for ischemic stroke and 
ICH.  
 
Elevated blood pressure is a risk factor for all stroke subtypes (Leppälä et al. 1999a). 
Medical treatment of hypertension reduces the risk of ischemic stroke by 32% (Goldstein 
et al. 2011), and halves the risk of ICH (Broderick et al. 2007). Evidence on SAH risk 
reduction with treatment of blood pressure is lacking, although patients with treated blood 
pressure have a better prognosis after SAH (Bederson et al. 2009). Hypertension is the 
most important modifiable risk factor for both ischemic stroke and ICH, but its relative 
importance is larger in ICH (O'Donnell et al. 2010). 
 
Smoking has been identified decades ago as a strong risk factor for SAH (OR 2.9; 95% CI 
2.5-3.5), less so for ischemic stroke (OR 1.9; 1.7-2.2), while protection against ICH has 
been suggested in an earlier meta-analysis (OR 0.74; 0.56-0.98) (Shinton and Beevers 
1989), but this was in the era before solid diagnostics with CT imaging. While the 
association of smoking risk with SAH and IS is rather proven (Bederson et al. 2009), also 
in Finland (Fogelholm and Murros 1987; Juvela et al. 1993), the evidence regarding 
smoking and the risk of ICH is more conflicting, with some studies showing an 
independent increased risk (Kurth et al. 2003a; Kurth et al. 2003b; Broderick et al. 2007; 
O'Donnell et al. 2010), while earlier studies performed in Finland did not show any 
association (Fogelholm and Murros 1993; Juvela et al. 1995), and a previous meta-
analysis showed smoking to protect from ICH (Shinton and Beevers 1989). Smoking 
cessation reduces the risk of ischemic stroke by 50% in one year, and the risk from 
previous smoking disappears in 5 years after quitting cigarettes (Goldstein et al. 2011). 







No clear association with elevated blood cholesterol and stroke mortality was found in a 
systematic meta-analysis, except for a subgroup of ischemic stroke patients younger than 
60 years of age, and elevated cholesterol was inversely associated with mortality in the 
older age groups (Lewington et al. 2007). Lower mortality with higher cholesterol could 
be explained by less severe strokes in patients with high cholesterol (Olsen et al. 2007). 
and statins may play a role (Elkind et al. 2005). While higher cholesterol may produce 
more ischemic strokes, some studies have not confirmed this (O'Donnell et al. 2010), and 
there seems to be an inverse relationship in ICH patients, as higher cholesterol, and lower 
HDL cholesterol may protect from hemorrhagic stroke (Tirschwell et al. 2004; O'Donnell 
et al. 2010), especially in the older patients (Lewington et al. 2007). Overall, it seems that 
the relationship between cholesterol and stroke is not quite straightforward, with inverse 
relationships between cholesterol effect on ischemic and hemorrhagic stroke possibly 
counterbalancing each other (Goldstein et al. 2011). 
 
While diabetes, cardiac disease, and systemic atherosclerosis are risk factors for ischemic 
stroke, their prevention coincides with the prevention of the stroke. Tight carotid artery 
stenosis is a special risk factor for stroke where medical prevention may be augmented 
with surgery in certain patients (Brott et al. 2011). Atrial fibrillation should be treated 
with anticoagulants when other risk factors of stroke are present (Goldstein et al. 2011). 
Scoring systems, such as CHADS2 (Gage et al. 2001), or its improvements (Lip et al. 
2010a; Lip et al. 2010b), may be used in deciding whether anticoagulation should be 
initiated. Although diabetes is a clear risk factor for all stroke subtypes (Sarwar et al. 
2010), tight glycemic control does not reduce the risk of stroke once diabetes has 
developed (Goldstein et al. 2006). Hormone replacement therapy and oral 
contraceptives are risk factors for ischemic stroke, and should be stopped after a stroke or 
TIA (Furie et al. 2011; Goldstein et al. 2011; Lindsberg et al. 2011). Other known 
modifiable risk factors are (Goldstein et al. 2006): obesity, physical inactivity, alcohol 
and drug abuse (Hillbom and Kaste 1978; Hillbom and Kaste 1983; Hillbom et al. 1995; 
Hillbom et al. 1999; Numminen et al. 2000b; Mostofsky et al. 2010; O'Donnell et al. 
2010), hyperhomocysteinemia, infections and inflammation including upper respiratory 
tract infections, caries, and paradentosis (Syrjanen et al. 1988; Syrjanen et al. 1989), 
elevated CRP (Kaptoge et al. 2010), migraine (Schurks et al. 2009), sleep apnea and 
snoring (Palomäki et al. 1989), but the effect of treating any of these is yet unknown 
(Goldstein et al. 2006). Even a diet rich in sausages has been identified as a stroke risk 
factor (Larsson et al. 2011). In addition to prevention of stroke, medications may also 
produce less severe strokes, as has been demonstrated with statins (Elkind et al. 2005) and 
beta blockers (Laowattana and Oppenheimer 2007).  
 
Risk factors of stroke have steadily declined in Finland since the 1970’s, where the best 
observational data comes from the eastern Finland provinces of North Karelian and 
Northern Savo, but has mainly been studied in populations younger than 75 years of age. 
Mean total serum cholesterol has declined from 6.9 mmol/l in 1972 to 5.3 mmol/l in 2007. 
Mean blood pressure has fallen accordingly, from 151/92 mmHg to 134/80 mmHg. 





Obesity (body mass index above 30) is the only risk factor which has not declined, but 
rather increased from 11 to 25 % in men, and stayed stable at 22% in women (Vartiainen 
et al. 2010). 
 
Risk Factors of Stroke 
Summary points 
 
1. Advanced age, male sex, non-white race, and a family history of stroke are the main 
non-modifiable risk factors of stroke, age being the most important. 
2. Hypertension, dyslipidemia, smoking, excessive alcohol consumption, physical 
inactivity, and obesity are the main modifiable stroke risk factors. 
3. Several other factors which are known to increase the risk of stroke exist, but the 
effectiveness of treating these is unknown. 
4. The risk factors for ischemic stroke, intracerebral hemorrhage, and subarachnoid 
hemorrhage are similar, but they differ in their magnitude. 
5. In Finland, hypertension, dyslipidemia, and smoking have declined steadily for 35 








2.4 Treatment of Stroke 
Treatment of stroke includes multiple overlapping processes, all of which aim to preserve 
and restore the functions of the affected brain tissue. Acute interventions target tissue at 
risk; organized care delivers an optimal environment to prevent further damage to the 
brain and other organ systems; restorative rehabilitation enhances the plastic capabilities 
of the brain; and secondary prevention aims to avert stroke recurrence. All of these are 
started right after the stroke. Guidelines on the treatment of stroke have been published in 
the USA (Adams et al. 2007; Bederson et al. 2009; Morgenstern et al. 2010; Brott et al. 
2011; Furie et al. 2011), Europe (EUSI 2000; Olsen et al. 2003; Brainin et al. 2004; 
Steiner et al. 2006; ESO 2008), and also in Finland (Kaste et al. 1979; Simonen et al. 
1989; Kaste et al. 2006; Lindsberg et al. 2011). 
2.4.1 Acute interventions 
In all subtypes of stroke, brain damage due to ischemia or hemorrhage may progress over 
the first hours to days. Therefore, rapid recanalization of the occluded vessel in ischemic 
stroke can reduce final brain damage, and evacuation of hematomas and closure of 
ruptured vessels in hemorrhagic stroke can save viable tissue. All such attempts have risks 
involved, and may benefit some patients, while being harmful to others. 
 
Thrombolytic therapy for stroke was first tested in the year 1958 with plasmin (Sussmann 
and Fitch 1958), and a full dozen different agents affecting the various steps of the 
coagulation and fibrinolytic cascades have been tested in humans since (Meretoja and 
Tatlisumak 2006). The only evidence-based recanalization strategy in ischemic stroke to 
date is recombinant tissue-type plasminogen activator alteplase, when used within 4.5 
hours from symptom onset (The National Institute of Neurological Disorders and Stroke 
rt-PA Stroke Study Group 1995; Hacke et al. 2008; Wardlaw et al. 2009; Lees et al. 
2010), with a number-needed-to-treat (NNT) of 5 to reach an excellent outcome if 
treatment is initiated within 1½ hours, 9 when administered from 1½ to 3 hours, and 15 if 
the delay is from 3 to 4½ hours (Lees et al. 2010).  
 
While tenecteplase and desmoteplase were the latest rivals aiming at reducing the 
hemorrhagic complications and extending the time-window of thrombolytic therapy for 
stroke (Meretoja and Tatlisumak 2008), the latest trials of both substances failed (Hacke et 
al. 2009; Haley et al. 2010). A further study of desmoteplase is recruiting patients, but the 
current challenge is to deliver the effective alteplase treatment to all eligible patients, as 
the thrombolysis rates among ischemic stroke patients reported in Sweden (6.6% of the 
18-80 year old patients in the year 2008) (Eriksson et al. 2010) and USA (5% of all age 
groups in the year 2009) (Fonarow et al. 2010) are low. It has been estimated that under 
ideal conditions thrombolytic rates could be around 25% (CASPR Investigators 2005). 





stroke, and the more restricted labeling in Europe is likely to reduce thrombolysis rates, 
although many of the contraindications are not evidence-based (Meretoja et al. 2010b). 
 
As only half of the occluded vessels re-canalize with intravenous thrombolysis (Rha and 
Saver 2007), more effective strategies have been sought. Enhancement of the thrombolytic 
agent with transcranial ultrasound has been shown feasible (Alexandrov et al. 2004). Intra-
arterial thrombolysis with pro-urokinase has been shown effective, with a NNT of 7, but 
the drug is not licensed or available (Furlan et al. 1999; O'Rourke et al. 2010). 
Intravenous followed by intra-arterial approaches have been studied in small pilot studies 
(Lewandowski et al. 1999; The IMS Study Investigators 2004; The IMS II Trial 
Investigators 2007), and a larger IMS III trial is underway. Mechanical and ultrasound-
based devices have been licensed for intra-arterial retrieval, stenting, or disruption of the 
blood clot, but none of these have been tested in randomized controlled trials (O'Rourke et 
al. 2010; Molina 2011). 
 
When recanalization fails, or a very large infarction develops despite recanalization, there 
is a risk of malignant and fatal brain edema. Early decompressive surgery, i.e. 
hemicraniectomy, is life-saving in this context, and improves patient functional outcome, 
but has been tested in randomized controlled trials only in patients younger than 60 years 
of age (Vahedi et al. 2007; Molina and Selim 2011). Hypothermia is being tested in trials, 
but no effect has been shown so far (Hemmen et al. 2010). 
 
For ICH, acute treatment can be conservative or operative. Activated recombinant factor 
VII has been studied in randomized double-blind placebo-controlled trials, but the 
promising results of the earlier trials (Mayer et al. 2005) could not be proven in the pivotal 
trial (Mayer et al. 2008). When coagulation disorders, thrombocytopenia, or medical 
anticoagulation are involved, fresh frozen plasma, vitamin K, and/or coagulation 
concentrates can be administered to stop the hemorrhage (Morgenstern et al. 2010). When 
the intracranial pressure (ICP) is elevated, reasonable treatment options include ventricular 
drainage, and surgical ICH removal. Trials on surgery are scarce (Juvela et al. 1989; 
Mendelow et al. 2005), and the recent guidelines state that for most patients, the benefit of 
surgery is unclear. Exceptions are patients with cerebellar hemorrhage with deteriorating 
consciousness and/or CSF blockage; these patients should be operated as soon as possible. 
Also some patients with large lobar hemorrhages close to the brain surface may benefit 
from surgery (Morgenstern et al. 2010). Most patients with ICH should be treated 
conservatively. 
 
For aneurysmal SAH, the acute treatment options are open surgery clipping and intra 
vascular coiling of the aneurysm. The decision between these two treatment options can be 
made at individual patient level, and both options should be available in centers treating 







2.4.2 Organized inpatient care 
Organized inpatient care of stroke patients has had various definitions, but usually refers 
to specialized hospital care of stroke patients involving a multidisciplinary team ( nurses, 
doctors, therapists), in a distinct geographic area (stroke unit) (Stroke Unit Trialists' 
Collaboration 1997; Stroke Unit Trialists' Collaboration 2007). Different studies have 
been more or less strict as to whether other patients can be treated in a stroke unit, and the 
units studied have thus been either only for stroke patients, or included a mixed variety of 
other patients. 
 
Over an average follow-up of one year, stroke ward care reduces the relative risk of death 
by 18%, NNT 22; death or institutional care by 14%, NNT 17; and death or dependency 
by 7%, NNT 24 (Stroke Unit Trialists' Collaboration 2007). Mobile stroke teams without 
a specific ward or unit are inferior in both patient outcome and cost (Norrving and Adams 
2006; Stroke Unit Trialists' Collaboration 2007).  
 
Stroke unit care can be delivered in various settings, either involving only acute patients 
for a few days (acute stroke unit), only rehabilitation patients after a delay of usually a 
week (rehabilitation stroke unit either solely for stroke patients, or mixed with other 
rehabilitation patients), or both (comprehensive stroke unit). Acute stroke care can be 
intensive, with constant monitoring, high levels of nursing, and possibility for life-support; 
semi-intensive, as above, but without life-support; or non-intensive (Stroke Unit Trialists' 
Collaboration 2007). The Cochrane review, gathering all available evidence, could find no 
difference in patient outcome between these various stroke unit types.  
 
In a Finnish randomized trial over the years 1987 to 1989, before there were stroke units 
in Finland, patients treated at the department of neurology have been shown to have a 
better functional outcome than patients treated at the department of medicine. Patients 
treated by a multidisciplinary team at the department of neurology were able to leave the 
hospital on average 16 days earlier. Out of 100 patients, 13 more could be discharged 
home, and at 1-year follow-up 17 more were independent in their activities of daily life   
(Kaste et al. 1995). The comprehensive, intensive or semi-intensive, model of stroke unit 
care has since become dominant in Scandinavian and German stroke care. Swedish 
registries of observational data have repeatedly supported the use of stroke units 
(Stegmayr et al. 1999; Glader et al. 2001; Terént et al. 2009). Observational data from 
Germany also support a semi-intensive stroke unit over conventional care (Walter et al. 
2009).  
 
Efforts have been made to identify which components in stroke unit care count 
(Langhorne and Pollock 2002) and first detailed guidelines were published in Europe by 
the European Stroke Initiative (EUSI) in 2004 (Brainin et al. 2004) and have been updated 






Organization of stroke care has advanced beyond stroke units and in-hospital phase, and it 
has been realized that a full chain of recovery should be involved, including primary 
prevention, emergency medical systems, acute care and rehabilitation, long-term follow-
up, public education, community campaigns, and research (NINDS Task Force 2003). The 
concept of stroke centers has been developed to encompass these functions.  
 
The Brain Attack Coalition in the USA published in the year 2000 consensus criteria for 
Primary Stroke Centers (PSC) (Alberts et al. 2000), later followed by criteria for even 
more specialized Comprehensive Stroke Centers (CSC) (Alberts et al. 2005), which more 
readily fulfilled the center-of-excellence concept including the whole chain of recovery. 
While stroke center designation has been shown to improve rates of thrombolytic therapy, 
no effect on patient outcome has been demonstrated (Morgenstern et al. 2002; Lattimore 
et al. 2003; Rymer et al. 2003; Wojner-Alexandrov et al. 2005). Despite this, the Joint 
Commission in the USA has certified stroke centers since 2003, and certification status 
may determine hospital reimbursements. 
  
EUSI performed a survey in Europe to evaluate expert opinion on what should be included 
in primary and comprehensive stroke centers (Leys et al. 2007b). In a study of European 
stroke facilities in 25 European countries, only 8.5% of 885 hospitals involved in the 
treatment of stroke patients met the criteria for stroke centers  (Leys et al. 2007a). Only 
13.5% of stroke patients, i.e. one out of seven were admitted to these specialized centers. 
Thus, in Europe, a solid network of stroke centers is far from achieved. The ESO 
Taskforce for stroke unit certification is working to increase the number of certified stroke 
units and to improve the chance of future stroke patients to have access to high quality 
stroke care. 
2.4.3 Rehabilitation 
Less than one third of stroke patients fully recover; rehabilitation is an option for the rest 
(ESO 2008). Organized multidisciplinary rehabilitation of stroke patients is evidence-
based medicine (Langhorne and Duncan 2001).  
 
Numerous specific interventions have been evaluated: 
 While physiotherapy in general is beneficial, especially if initiated early (Van 
Peppen et al. 2004; Pollock et al. 2007), movement constraint therapy (Sirtori et 
al. 2009), treadmill training (Moseley et al. 2005), or simultaneous bilateral 
training (Coupar et al. 2010) is not. Repetitive tasks improve ADL functions, but 
no benefit has been shown after the therapy is stopped (French et al. 2007). Over 
ground physical therapy gait training, and fitness training both improve patient 
speed, but no effect on disability has been shown (Saunders et al. 2009; States et 
al. 2009). Music therapy may be beneficial for training to walk after stroke (Bradt 






 Speech therapy for aphasia following stroke is effective in general (Kelly et al. 
2010), but no specific techniques have been shown superior to one another. More 
intensive therapy is more effective. Speech therapy is as effective when 
administered by a trained volunteer or relative, as when administered by a therapist 
(Kelly et al. 2010). Therapies for dysarthria have not been studied (Sellars et al. 
2005). 
 Occupational therapy improves patient outcome and likelihood of independence in 
ADL functions (Legg et al. 2006), but not cognitive abilities (Hoffmann et al. 
2010). 
 Cognitive therapy does improve alertness and attention, but not memory, neglect, 
or independence (Lincoln et al. 2000; Bowen and Lincoln 2007; Nair and Lincoln 
2007).  
 No effective rehabilitation interventions for motor or speech apraxia (West et al. 
2005; West et al. 2008),or sensory impairments (Doyle et al. 2010) have been 
identified. 
 
In addition to stroke unit and other inpatient rehabilitation (Langhorne and Duncan 2001), 
also outpatient therapy is effective (Outpatient Service Trialists 2003). There is no 
evidence to support continuing rehabilitation for more than a year after stroke (Aziz et al. 
2008), although effects of therapy administered six months after stroke are still noticeable, 
albeit they no longer affect ADL function (Ferrarello et al. 2011). Ultra-early 
rehabilitation, within 24 hours of stroke, is feasible, but adverse events and benefit are 
unclear (Bernhardt et al. 2009). Also people in permanent long-term care benefit from 
rehabilitation (Forster et al. 2009). Rehabilitation for stroke in Finland is far from 
optimal, large geographic variations exist on service availability, and there is much room 
for improvement (Wikström et al. 2009). 
2.4.4 Secondary prevention 
A quarter of stroke cases are recurrences (Furie et al. 2011), and all patients with a history 
of stroke must be considered at an increased risk for recurrent strokes. Secondary 
prevention should always be individually tailored, and depends on stroke subtype and 
etiology, as well as patient’s risk factor profile, motivation, and cognition. Most ischemic 
stroke patients benefit from antithrombotic, antihypertensive, and lipid lowering 
medications, and some from carotid interventions. ICH patients mainly benefit from 
antihypertensives, while the secondary prevention of SAH is based on closure of 
aneurysms, possible screening for development of further aneurysms, and quitting of 
tobacco smoking. Life-style modifications are important in all stroke subtypes.  
 
Antithrombotics 
The efficacy of warfarin in the secondary prevention of stroke in atrial fibrillation patients 





(European Atrial Fibrillation Trial Study Group 1993), and SIFA (Morocutti et al. 1997). 
Combined, these trials showed a 51% annual stroke risk reduction when compared to 
antiplatelets (Saxena and Koudstaal 2004). Stroke secondary prevention with warfarin is 
evidence-based only in atrial fibrillation. For atherothrombotic stroke, antiplatelet drugs 
are more effective. 
 
Acetylic salicylic acid (ASA) is 13% more effective than placebo in the secondary 
prevention of stroke (Sandercock et al. 2008). The combination of extended release 
dipyridamole and ASA is superior to ASA alone, as shown in ESPS 2 (Diener et al. 1996) 
and ESPRIT studies (Halkes et al. 2006). Clopidogrel showed a non-significant trend 
towards better secondary prevention than ASA in the CAPRIE trial (CAPRIE Steering 
Committee 1996) and was as effective as the combination of ASA and dipyridamole in the 
PROFESS trial (Sacco et al. 2008).  
 
Antihypertensives 
Antihypertensive medication is indicated after IS, even in normotensive patients (Furie et 
al. 2011). While many large studies, like ALLHAT (ALLHAT Authors/Officers and 
Coordinators 2002), LIFE (Dahlof et al. 2002), MOSES (Schrader et al. 2005), and 
ONTARGET (Yusuf et al. 2008b), have studied antihypertensives in secondary prevention 
of stroke, these did not include a placebo arm. The HOPE trial showed a 32% annual 
reduction in strokes with ramipril when compared to placebo, but this was not a stroke 
secondary prevention trial, as only 11% of the participants had a history or stroke (Yusuf et 
al. 2000; Bosch et al. 2002). 
 
The proof of antihypertensive efficacy in stroke secondary prevention comes from the 
following trials and meta-analyses: 
 PATS, indapamide vs. placebo, n=5665, relative risk reduction (RRR) 29% with 
active treatment (PATS Collaborating Group 1995) 
 INDANA-meta-analysis of 8 smaller trials, mainly diuretics vs placebo, n=1087, 
RRR 29% (Gueyffier et al. 1997)  
 PROGRESS, perindopril ± indapamide vs. placebo, n=6105, RRR 28%, the benefit 
coming mostly from the combination therapy, which benefited also normotensive 
patients (PROGRESS Collaborative Group 2001) 
 ACCESS, candesartan vs. placebo, n=339, RRR 34% (Schrader et al. 2003) 
 PROFESS, telmisartan vs. placebo, n=20 332, non-significant RRR 5% (Yusuf et 
al. 2008a) 
Combined, these show a relative 16% annual decrease (OR 0.84; 95% CI 0.78 - 0.90) in 
stroke recurrence with antihypertensive medication use (Meretoja 2009). Diuretics, either 
alone or with ACE-inhibitors are the preferred initial choice for antihypertensive 









Lipid lowering strategies after IS have been given lower target values year after year. The 
most recent American guidelines suggest LDL cholesterol should be reduced by 50% after 
IS, or reduced to <1.8 mmol/l (Furie et al. 2011).  
 
The proof of statin efficacy in stroke secondary prevention comes from two large trials. 
The HPS trial randomized 20 536 high-risk patients to simvastatin or placebo, and showed 
an annual stroke RRR of 25% (Heart Protection Study Collaborative Group 2002). 
However, most of the patients involved in this study were not stroke patients. In a post-
hoc analysis of stroke, TIA, or carotid surgery patients (n=3280), no benefit from statin 
could be shown in secondary prevention of stroke, although the treatment reduced the 
combined end-point of vascular death, myocardial infarction, and stroke (Collins et al. 
2004). 
 
The only current proof of benefit from statin use after stroke comes from the SPARCL 
study, where 4731 patients were randomized to atorvastatin or placebo, and annual stroke 
recurrence decreased by 15% with active treatment (Amarenco et al. 2006).  
 
Although both lower cholesterol (Tirschwell et al. 2004; Lewington et al. 2007), and statin 
use (Heart Protection Study Collaborative Group 2002; Collins et al. 2004; Amarenco et 
al. 2006) are associated with an increased risk of ICH, post-ICH statin use does not seem 
to result in increased ICH recurrence (FitzMaurice et al. 2008). Statins should be 
continued after ischemic stroke, as quitting is especially harmful (Colivicchi et al. 2007). 
 
Carotid procedures 
Tight carotid artery stenosis is a major risk factor for stroke, and it should be screened for 
acutely in ischemic stroke and TIA patients. Symptomatic stenosis patients benefit more 
from carotid endarterectomy (CEA), with NNT to prevent one annual ipsilateral stroke in 
cases of tight stenosis between 12 and 27 depending on how severe the carotid stenosis is 
(Brott et al. 2011), and lower when operated early within 2 weeks of symptoms (Rothwell 
et al. 2004). Asymptomatic stenosis operation NNT values are high, from 84 to 1351, and 
should be performed only in cases where perioperative risks are low (Brott et al. 2011). 
Carotid stenting is a therapy alternative to CEA, but has worse long-standing protective 
effect than CEA, does not reduce complications, and should be performed in selected 
patients only (Rothwell 2010; Economopoulos et al. 2011). 
 
Lifestyle modification 
Smoking should be quit, especially after a stroke. Counseling, nicotine products, and oral 
smoking cessation medications are evidence-based in helping quit smoking (Furie et al. 
2011). Heavy drinking should also be quit because it is associated with increased risk of 
both ischemic and hemorrhagic stroke and quitting should be encouraged. It may be safe 
to drink 1 to 2 drinks per day, which may even reduce the risk of ischemic stroke 
(Palomaki and Kaste 1993), although not something to advise (Furie et al. 2011). Obesity 





physical activity are likely to reduce other risk factors of stroke, such as hypertension, 
impaired glucose tolerance, and lipid disorders, and should therefore be encouraged. 
However, no studies have shown that smoking cessation, reduction of alcohol 
consumption, reduction of weight, or increase of physical activity would reduce stroke 
recurrence (Furie et al. 2011). 
 
 
Treatment of Stroke 
Summary points 
 
1. Treatment of stroke is well guided by detailed national and international guidelines. 
2. Recanalization should be attempted in ischemic stroke patients when possible. Only 
intravenous alteplase within 4.5 hours of symptom onset is evidence-based for this 
purpose.  
3. Ruptured aneurysms should be closed in SAH patients, and choice between clipping 
and coiling is done on individual basis. 
4. Most ICH patients do not benefit from ICH evacuation. 
5. Acute stroke treatment should take place in a stroke unit. 
6. Stroke centers, encompassing all the functions of the chain of recovery before and 
after a stroke unit, have been described, but their efficacy is unproven. 
7. Rehabilitation after stroke is needed in most patients, is evidence-based as a whole, but 
data from randomized controlled trials on details and techniques is limited. 
8. Secondary prevention of stroke should include antithrombotics, antihypertensives, and 
lipid lowering agents in most and carotid procedures is selected ischemic stroke 
patients, antihypertensives in ICH patients, and aneurysm closure in SAH patients. 








2.5 Outcome of Stroke 
2.5.1 Mortality 
Stroke caused 5.7 million deaths worldwide in the year 2004, 9.7% of all deaths (58.8 
million), and second only to all cancers together (7.4 million, 12.6%) and ischemic heart 
disease (7.2 million; 12.2%) (WHO 2008). National income is a stronger predictor of 
stroke mortality than are cardiovascular risk factors. Age-adjusted mortality rates vary by 
a factor of 10 among countries (Johnston et al. 2009). Stroke causes 1/18 (5.6%) of all 
deaths in the USA. A 15% fall in absolute number of deaths, and a 45% decrease in age-
adjusted death rate has been observed from 1997 to 2007 (Roger et al. 2010). 
 
Figure 1 presents the official Finnish mortality statistics from 1969 to 2009. Statistics 
Finland reports that the data is otherwise comparable in time, but over the years 2005 - 
2006 the classification was changed in such a way that pneumonia alone was no longer 
considered the cause of death if another long-term disease was mentioned in the death 
certificate. This decreased pneumonia deaths by about a third, and these cases were mostly 
coded as dementia or cerebrovascular disease (www.stat.fi, accessed 18th Jan 2011). It is 
noteworthy from the data in Figure 1, that although the total population has grown by 
15%, from 4 614 277 to 5 351 427, and the number of population older than 75 years of 
age has more than tripled, from 120 962 to 427 079, the number of stroke deaths has 
decreased by 32%, from 6455 to 4380.  
Figure 1.  Trends in causes of death in Finland over the years 1969 to 2009.  
The five most significant causes of death in the year 2009 are presented, which together 





















Finnish age-adjusted mortality from cerebrovascular disease almost halved in the period of 
1969 to 1982 (Tuomilehto et al. 1986). Most of the reduction was due to reduction in ICH 
(Tuomilehto et al. 1984). Over the years 1982 to 2009, the age-adjusted mortality has 
continued to decrease by another 56% (www.stat.fi, accessed 18th Jan 2011). 
 
The decrease in stroke mortality could be either due to decreased incidence of stroke, or 
decreased case-fatality after stroke, but is most likely a combination of these (Kotila 1984; 
Tuomilehto et al. 1993; Numminen et al. 2000a; Lehtonen et al. 2004; Sivenius et al. 
2004). Changes in classification of causes of death could be a third explanation, but this 
has been considered unlikely (Sarti 1993; Sarti et al. 1993). 
2.5.2 Case-Fatality 
Early case-fatality has been reported in most population-based incidence studies of stroke. 
In high-income countries, overall stroke one-month case-fatality has declined from around 
35% in the 1970’s to around 20% in the 2000’s. It has been suggested that the reductions 
in early case-fatality rates reflect improved risk factor control and more widespread use of 
medications (ASA, antihypertensives, and statins) before stroke, rather than changes in 
acute care. Even in the 2000’s, there was little difference in the early case-fatality rates 
between high-income and low to middle income countries among ischemic stroke (14% 
vs. 17%) or ICH patients (41% vs. 39%), but a larger difference in SAH patients (30% vs. 
44%) (Feigin et al. 2009). 
 
The 28-day case-fatality from all stroke has been 32% in North Karelia, and 38% in 
Espoo-Kauniainen in the 1970’s (Puska et al. 1974), and the median survival after ICH in 
the 1972-3 was as low as 3 days (Aho 1975). The case-fatality rates depend strongly on 
stroke severity, patient age, and stroke subtype. Age-adjusted stroke severity has 
decreased in Finland from the 1972 to the 1991, as shown in two population-based 
registries (Numminen et al. 2000a). 
 
According to the FINMONICA and FINSTROKE studies, 28-day case-fatality of all 
stroke has declined in the <75 year olds from 1983 to 1997 from 21.9% to 18.6% 
(Sivenius et al. 2004), and was 36.6% in the >75 year olds in the year 1997 (Lehtonen et 
al. 2004). The 28-day case-fatality rate for all stroke patients was thus 28.2% in the year 
1997. 
 
The likelihood of dying is permanently increased also in stroke patients surviving the 
acute phase. All-cause annual fatality rates of stroke survivors after one year since stroke 







Prevalence is more difficult to measure than incidence or mortality, and estimates are 
either based on extrapolations from incidence and mortality data, or from surveys. The 
worldwide prevalence of stroke has been estimated at 30.7 million in the year 2004, and 
12.6 million are living with moderate to severe disability. A total of 9.6 million stroke 
survivors live in Europe (WHO 2008). The prevalence of stroke in the USA has been 
estimated as 7 million stroke patients, 3% of the population aged 20 or over (Roger et al. 
2010). This figure is expected to increase to 4% by the year 2030 (Heidenreich 2011).  
 
In Finland, the prevalence of stroke was estimated in the SII Mobile Clinic Health 
Examination Survey in 1973 to 1976, based on the question: "Have you had a stroke that 
has been diagnosed by a doctor?". Of the patients who answered affirmatively, only 53% 
truly had had a stroke after review of medical data. A national stroke prevalence of 26 300 
(0.6%) for the whole country was estimated (Aho et al. 1986). 
 
In a prevalence study performed in the Jyväskylä area in 1989, 471 stroke patients in 
institutional care were identified, which represented about half of all stroke survivors. The 
data on total prevalence presented in the study is somewhat ambiguous, but has been 
estimated at 41 000 (0.8%) in the whole of Finland (Rissanen 1992; Kaste et al. 2006). 
 
The Health 2000 survey in the year 2000 was carried out in a population of 6770 adults 
aged over 30 years of age. Stroke prevalence, based on an interview and a physical 
examination, was 2.3% in men and 1.3% in women (Aromaa and Koskinen 2004). This 
corresponds to about 60 000 people in the population aged over 30 years of age, or 1.2% 
of the total population in the year 2000.   
2.5.4 Disability, late post-stroke complications, and quality of life 
Disability and functional outcome 
Worldwide, stroke is the sixth most important cause of disability, as measured by 
disability adjusted life years (DALY), after lower respiratory tract infections, diarrhea, 
depression, ischemic heart disease, and HIV/AIDS. Stroke is responsible for a loss of 46.6 
million DALYs annually, 3.1% of all DALYs lost due to disease. In high-income 
countries, stroke is the number three cause of disability, after depression and ischemic 
heart disease, and accounts for 4% of all disease-related disability  (WHO 2008).  
 
Validated scores to evaluate functional outcome after stroke have been developed (Kasner 
2006), such as the modified Rankin Scale (mRS) (Rankin 1957; van Swieten et al. 1988; 
Banks and Marotta 2007), and Barthel Index (Mahoney and Barthel 1965). In stroke 
trials, it has become practice to measure outcome at 3 months after stroke, and the mRS in 
its simplicity is the most widely used measure. The mRS does not have a ceiling effect 






Functional outcome has been looked at also in Finnish population-based studies. Aho 
evaluated the patients for 3-month mRS, and 14% of patients had an excellent outcome (0-
1), 39% a good outcome (0-2), 46% a moderate outcome (0-3), while 40% were dead (6) 
(Aho 1975). In the study by Rissanen, mRS was evaluated at one year, when 15% (40/266) 
had an excellent outcome, 33% a good outcome, 49% a moderate outcome, and 37% were 
dead (Rissanen 1992). 
 
Late post-stroke complications 
In addition to the obvious motor, speech, sensory, and visual deficits caused by a stroke, 
several complications may develop later on as a result of the stroke. 
 
Low mood is a natural reaction to disability caused by a stroke, but can become 
depression if prolonged and severe. Post-stroke depression is common, but the estimates 
in studies vary from 18% to 61% depending on criteria and time of evaluation (Gainotti 
and Marra 2002). Although early depression predicts poor outcome (Pohjasvaara et al. 
2001; Willey et al. 2010) the mood disorder is likely to resolve spontaneously as time goes 
by (Hackett et al. 2005b), which may be augmented with support systems (Kotila et al. 
1998) and medications (Hackett et al. 2005a). Antidepressants may improve rehabilitation 
results (Chollet et al. 2011). Depression in caregivers of stroke survivors is common (Berg 
2010). 
 
Dementia is a frequent outcome after stroke, either due to the stroke, due to other 
pathology existing in the elderly patients, or a combination of these (Leys et al. 2005; 
Erkinjuntti 2007), and can range from mild cognitive decline to severe dementia, together 
called vascular cognitive decline (Erkinjuntti and Gauthier 2009). Post-stroke or vascular 
dementia can be defined with various criteria which can give widely differing estimates of 
prevalence in the same patient population, from ~6% to ~27% (Wetterling et al. 1996; 
Pohjasvaara et al. 1997). Also dementia prior to stroke is common, and strongly affects 
the outcome of stroke patients (Henon et al. 2003; Melkas et al. 2009). Unfortunately 
there are no evidence-based specific medications for vascular dementia (Kavirajan and 
Schneider 2007), and the treatment concentrates on stroke secondary prevention and 
control of symptoms.  
 
Epilepsy in the old age is most often a result of a prior stroke, stroke is the most common 
cause of secondary epilepsy in all age groups, and 2-4 % of stroke patients develop 
epilepsy (Bladin et al. 2000; Camilo and Goldstein 2004; Benbir et al. 2006). Seizures at 
the acute phase of stroke rarely reoccur, but more than half of patients with later seizures 
do develop epilepsy, and these patients require antiepileptic medications (De Reuck et al. 
2008b). Certain infarct localizations, cortical involvement, and temporo-parietal regions, 
and more severe strokes predict a higher risk of post-stroke epilepsy (Bladin et al. 2000; 
De Reuck et al. 2008a), while the risk in hemorrhagic and ischemic strokes are fairly 







Spasticity is a common complication one year after stroke, affecting 17% to 39% of 
patients (Watkins et al. 2002; Lundstrom et al. 2008), and should be treated when it 
interferes with activities of daily living (Brainin et al. 2011). The treatment is usually 
multifactorial, and options include physiotherapy, systemic antispasmodic drugs, and 
botulinum toxin injections (Brainin et al. 2011). 
 
Other common late complication of stroke include pain (Jonsson et al. 2006), apathy 
(Brodaty et al. 2005), fatigue (Glader et al. 2002), anxiety (Morrison et al. 2005), and 
chronic posttraumatic stress symptoms (Bruggimann et al. 2006).  
 
Quality of life 
The perceived quality of life (QOL) after severe stroke may be judged very low, even 
negative i.e. worse than death, by healthy subjects, but much higher in stroke victims 
themselves (Murphy et al. 2001), reflecting the adaptive capabilities of the human psyche. 
In severe stroke, this coping usually takes at least half a year (Darlington et al. 2007). 
Measuring QOL in stroke patients with communication problems is a special challenge, 
but proxy ratings i.e. rating of QOL by a close relative or caregiver, have been deemed 
fairly valid when 6 months have passed since the stroke (Pickard et al. 2004). Reviews of 
QOL after stroke emphasize the main determinant of QOL, the initial stroke severity (Post 
et al. 2001; Tengs et al. 2001; Carod-Artal and Egido 2009). Stroke impact on caregiver 
QOL is significant when considering the total burden of the disease (Carod-Artal et al. 
2009). 
 
QOL has been measured in Finland, in 85 stroke survivors in Oulu (Kauhanen et al. 
2000), and in the Health 2000 study in 6770 citizens, out of which about 200 were stroke 
survivors (Aromaa and Koskinen 2004; Saarni et al. 2006). In the latter study, stroke 
diagnosis was based on self-reporting (2.8% prevalence), about 1/3 of which is incorrect 
after a physician’s assessment (Aromaa and Koskinen 2004). Among 29 chronic 
conditions evaluated, stroke was the fifth most important cause of loss of QOL, after 
Parkinson’s disease, arthrosis, anxiety disorders, and depression. Different QOL 








Outcome of Stroke 
Summary points 
 
1. Stroke is the number 3 cause of death worldwide, after cancer and coronary heart 
disease, accounting for 5.7 million deaths, or 10% of all deaths. 
2. About one in five stroke patients dies in the acute phase of stroke, and death is more 
likely in the old, with severe strokes, in ICH or SAH patients, and in low income 
countries. 
3. Stroke is a major cause of disability in the population. Late post-stroke complications, 
such as depression, cognitive decline, epilepsy, and spasticity contribute to this 
disability. 
4. In Finland, age-adjusted stroke mortality has fallen annually by 2.5% in the 70’s to 
80’s, and by 2% annually since, reflecting decrease in both incidence and case-fatality. 
5. Finnish stroke prevalence is increasing with improved survival. 
6. Functional outcome and QOL after stroke have been measured in too few Finnish 








2.6 Cost of Stroke  
Cost of stroke patients has been estimated to constitute between 1.6% and 6.9% of total 
healthcare costs in developed countries, with the latest estimates at around 3% (Evers et 
al. 2004). The direct medical costs of stroke in the USA are estimated at US$ 28.3 Billion 
in the year 2010, and this is expected to more than triple to US$ 95.6 Billion by the year 
2030 (2008 currency). During the same time, the indirect costs of stroke are estimated to 
increase from US$ 25.6 Billion to 44.4. Billion (Heidenreich 2011).  
 
Cost of illness studies on individual patients 
Cost of illness studies can be performed either top-down, i.e breaking the total sum of 
healthcare costs to their components, or bottom-up, i.e. from individual patient data. A 
latest systematic review of stroke cost literature was performed in the year 2009 (Luengo-
Fernandez et al. 2009) and identified 120 studies with patient-level data on at least 20 
patients from OECD countries. There were 6 larger studies with more than 10 000 
patients: (Mitchell et al. 1996), n = 37 000; (Chan et al. 1997), n = 76 400; (Samsa et al. 
1999), n = 49 000; (Reed et al. 2001), n = 31 000; (Deutsch et al. 2006), n = 58 000; (Caro 
et al. 2006), n = 19 000, while most studies included a few hundred patients. All of the 
studies were from 15 countries, and half of them published from data of USA, UK, or 
Swedish patients. There was significant variation in the cost estimates in these studies. 
Almost half of the studies evaluated only initial hospitalization costs. In the remaining 
studies, only few analyzed which of the costs were attributable to stroke based on previous 
resource use (n=7). Of all 120 studies, only 8 reported IS, ICH, and SAH costs separately. 
Mean 1-year costs of stroke or ischemic stroke in year 2006 values was US$ 28 500, but 
variation between studies was huge, ranging from US$ 7300 to US$ 146 000. Variation 
was mostly explained by differences in costs between countries, but variance within 
countries was also large (Luengo-Fernandez et al. 2009). 
 
Lifetime costs 
Lifetime direct costs per stroke patient have been estimated in some studies. In the USA, 
these have been estimated, in year 1990 US$ with 5% discounting of future costs, to be 
44 000 for IS, 33 000 for ICH, 61 000 for SAH, and 44 000 for total stroke (Taylor et al. 
1996). In Sweden, after some earlier cost of stroke studies (Terént 1983; Persson et al. 
1990; Thorngren and Westling 1991; Asplund et al. 1993),  these have been calculated, in 
1991 currency value and discounted at 5% per annum, to be US$ 73 000, of which 
US$30 000 was associated with stroke and the remaining 60% with old age and other 
disease (Terént et al. 1994). The lifetime cost of a stroke patient in the Netherlands, in 
1991 currency and no discounting, has been estimated for total stroke US$ 41 000, US$ 
43 000 in IS patients, and US$ 26 000 in ICH patients (Bergman et al. 1995). An estimate 
from Australia, in the year 1997 currency and 5% per annum discounting, was US$ 34 000 
(Dewey et al. 2001), later also reported according to subtype to be US$ 32 000 for IS and 
US$ 56 000 for ICH (Dewey et al. 2003). These figures also included indirect costs, which 





currency value, was 50 500 €, or 43 100 € after 3% discounting (Kolominsky-Rabas et al. 
2006).  
 
Costs in Finland 
Total healthcare spending in Finland corresponded to 8.4% of gross domestic product 
(GDP) in the year 2008, which is below OECD average 9.0%. The public sector finances 
74% of these costs, close to OECD average of 73% but lower than in most European 
countries (OECD 2010). In Finland, the lifetime cost of stroke has been estimated in one 
previous study, based on data from Jyväskylä region in the 1980’s (Kaste et al. 1998). In 
1991 currency, discounting of 5% per annum, the estimate was US$60 000, of which more 
than 90% was stroke-related. This corresponded to 6.1% of total healthcare costs, high in 
international comparison. The indirect costs may be, depending on estimate, either as large 
at the direct costs, or with the friction model, only 30% of the direct costs (Fogelholm et 
al. 2001). 
 
Costs attributable to stroke 
One-year costs of the year immediately prior to first-ever stroke have been reported in two 
Swedish studies as being in the amount of 53% (Terént et al. 1994) and 6% (Zethraeus et 
al. 1999) of the costs over the year immediately post stroke. The difference has been 
thought to be due to difference in age structure between the studies (Ekman 2004). In the 
USA, the costs one year prior to stroke have been in the amount of 30% of the costs of the 
first year of stroke (Leibson et al. 1996). 
 
Cost-effectiveness of specific components of care 
The costs associated with possible improvements in the primary prevention of stroke and 
myocardial infarction in the USA have been estimated, and the only intervention that was 
cost-saving was tobacco cessation campaigns. Low-cost antithrombotics had low cost per 
QALY, but the primary prevention interventions treating hypertension, diabetes, 
hypercholesterolemia, and obesity cost between 17 000 to 270 000 USD per QALY 
gained (Kahn et al. 2008). Primary prevention in the population may thus not 
automatically be a cost-effective way to fight stroke, although it has a huge potential to 
reduce stroke (Cadilhac et al. 2007), and from the human suffering point of view is 
preferred. Primary prevention with warfarin in atrial fibrillation is an exception, with good 
cost-effectiveness (Gustafsson et al. 1992; Mercaldi et al. 2011). Although stroke unit 
care is very effective, it is also expensive, and the data on cost-effectiveness of stroke unit 
care is controversial (Meretoja et al. 2010a). ASA, blood pressure medications, and statins 
have been considered cost-effective in ischemic stroke secondary prevention in general, 
while more expensive medications and interventions perhaps only in selected patients 








Cost of Stroke 
Summary points 
 
1. Treatment of stroke patients is expensive and consumes about 3% of all healthcare 
resources in developed nations. 
2. Cost of stroke has been studied in 15 OECD countries, mostly in the USA, UK and 
Sweden.  
3. In some studies ICH patients have had higher lifetime costs, while in others IS patients 
have been more expensive. Most studies do not report these separately. 
4. It is unclear how much of the costs of stroke patients actually are caused by the stroke, 






3 AIMS OF THE STUDY 
I To set up a nationwide database for monitoring stroke in Finland, using data from 
existing national registries. 
 
II To describe trends in national stroke case-fatality, and identify possible treatment-
related associations on these trends. 
 
III To test whether treatment in a stroke center is associated with patient outcome. 
 






4 PATIENTS AND METHODS 
4.1 The PERFECT project, organization, and timetable 
The PERFECT project was started in the year 2004 as a research co-operation between 
health districts, Social Insurance Institute (SII; KELA in Finnish), and the National 
Research and Development Centre for Welfare and Health (STAKES). The project has 
been co-ordinated by the Centre for Health and Social Economics (CHESS) of STAKES. 
STAKES has merged with the National Public Health Institute (KTL) from the beginning 
of the year 2009, to form the National Institute for Health and Welfare (THL). 
 
The PERFECT project aims to develop methodologies for systematic use of register-based 
data in the assessment of effectiveness and costs of major diseases. Seven costly diseases 
are modeled: stroke, myocardial infarction, breast cancer, schizophrenia, very preterm 
infants, hip fracture, and total hip arthroplasty. 
 
Research professor Unto Häkkinen is the director of CHESS and the whole PERFECT 
project. There was a general methodological group within CHESS to develop the methods 
involved in cost approximation and benchmarking. In addition to this, each of the disease 
groups had a steering group consisting of clinical experts and CHESS personnel. The 
PERFECT Stroke project included the following neurologists and CHESS experts: 
 
Atte Meretoja (secretary)  Helsinki University Central Hospital 
Markku Kaste Helsinki University Central Hospital 
Aimo Rissanen Jyväskylä Central Hospital 
Juhani Sivenius Kuopio University Hospital 
Matti Hillbom  Oulu University Hospital 
Terttu Erilä  Tampere University Hospital 
Reijo Marttila Turku University Hospital 
Risto O. Roine (chairman)  Helsinki University Central Hospital (-2006),  
Turku University Hospital (2006- )    
Merja Juntunen National Institute for Health and Welfare / CHESS 
Miika Linna  National Institute for Health and Welfare / CHESS 
Unto Häkkinen National Institute for Health and Welfare / CHESS 
 
In addition, systems analysts’ Eija Teitto (April 2004 to May 2005), Antti Liski (June 
2005 to November 2006), and Juha-Pekka Konttinen (December 2006 to April 2007) 
contributed to the early development of the PERFECT Stroke methodology, and chief 
nurse Anne Puumalainen of the Helsinki University Central Hospital Stroke Unit attended 
several planning meetings in the early years. The PERFECT Stroke steering group 
convened 4 times, in addition to which a small taskforce (Meretoja, Kaste, Roine, 
Häkkinen, Linna, and the current systems analyst) had 24 meetings over the years 2004 to 





The study was initiated in the first planning meeting on 5th April 2004. The details of 
coding, episode formation, and measurable definitions were done over the next two years. 
After approval of the regulative authorities, the large national registries were linked to 
obtain the data. The first database was formed in the summer of 2007 and the first 
standard reports published in late 2007 (Meretoja et al. 2007). Some corrections and 
methodological changes were made to the episode definition and coding the next year, and 
annual reports have been produced since, currently for the patients of the years 2003 to 
2008, available in Finnish at http://www.thl.fi/fi_FI/web/fi/tutkimus/hankkeet/perfect.  
 
No ethics committee approval or patient consent was required according to Finnish law, as 
the patients were not contacted, and the data was anonymized so that individual patients 
were not identifiable to the researchers. 
4.2 PERFECT Stroke dataset sources, patient selection, and 
register linkage 
Each Finnish citizen and permanent resident has an unique personal identification number, 
a system started in the year 1964, with full nationwide coverage in the year 1968 (Gissler 
and Haukka 2004). This number is comprehensively used in all administrative registries to 
identify a person, allows for reliable follow-up of a person within a registry, and makes 
linkage of various registries possible. 
 
The main source of the PERFECT project is the Finnish national Hospital Discharge 
Register (HILMO). This registry has been operating in Finland since 1967 and is run by 
THL (formerly STAKES). The HILMO register contains all hospital treatment episodes, 
including information on provider of care, first and last date of the episode, a primary 
diagnosis, several secondary diagnoses, and procedures performed during the hospital 
episode. In the year 1994, all social institutions, such as nursing homes, were added to 
HILMO (Gissler and Haukka 2004).  
 
A stroke patient is identified from the HILMO with an ICD-10 primary diagnosis of a 
cerebrovascular disease (Table 1). 
Table 1. Stroke subtype classification in the PERFECT Stroke project. 
ICD-10 code Stroke subtype Abbreviation 
G45  Transient ischemic attack TIA 
I60 Subarachnoid hemorrhage SAH 
I61 Intracerebral hemorrhage ICH 
I63 Ischemic stroke IS 
I62, I64-I68 Other cerebrovascular disease OTH 
Stroke syndromes (G46) were classified according to etiological subcode (I60 to I67), i.e. G46*I63.2 equals 






Only first occurrences are included. If a patient has a previous ICD-10 code I60-I69, or a 
corresponding ICD-9 code of 430-434 or 436-438 in the HILMO registry, they are 
excluded. Previous TIA is not an exclusion criterion. Thus TIA-patients may appear in the 
database twice; if they are first hospitalized for a TIA and later for a stroke. Previous 
cerebrovascular disease diagnoses are checked for in HILMO from year 1987 onwards. 
 
The patients identified with this approach are linked with personal identification numbers 
to the national CDR and the registries of SII. The CDR is only checked for to see if the 
patient has died, irrespective of cause. The registries of SII are used to check for any 
prescription medication purchases one year prior and one year post stroke, use of private 
medical services, and costs associated with both medications and private medical services. 
Also the SII Registers on Social Benefits are utilized to look for special reimbursement of 
medications in long-standing diagnoses. Sick leaves, and a linkage with the Registry of 
Pensions under the Finnish Center for Pensions, is also available, to estimate possible 
indirect costs due to lost productivity, but they are not reported, as indirect costs are 
outside the scope of this study. A distinct portion of HILMO, the discharge registry of 
social institutes, “social-HILMO”, is utilized in evaluating long-term institutional care, 
and direct costs associated with this care. For details of each of these registers, please see 
descriptive article (Gissler and Haukka 2004). 
4.3 Forming an episode 
An episode of care is formed from the data in HILMO. A patient has entries in the registry 
for each single hospital treatment according to treating specialty. For transfers between 
specialties, e.g. from internal medicine to neurology, separate entries are formed. For the 
purpose of the PERFECT Stroke database, these entries are joined, to estimate the total 
consecutive episode of in-patient care within and between hospitals. An episode starts 
with the first cerebrovascular disease diagnosis, and ends when the patient dies, is 
discharged and transferred home, or to a nursing home. New hospitalizations thereafter 
start a new episode. 
 
Sometimes a patient has their stroke while already hospitalized for another reason, 
sometimes the primary diagnosis is uncertain at the first hospital, and sometimes there are 
several 1-day episodes for a single day, when a patient is rapidly transferred from one 
hospital to another. If the episode starts with multiple different concurrent or consecutive 
cerebrovascular disease diagnoses, one of these has to be chosen as the subtype according 
to which the episode is classified. As hemorrhagic stroke diagnoses are more likely to be 
made only with positive diagnostic findings, while ischemic stroke diagnoses or undefined 
stroke may be diagnosed with clinical suspicion only, the diagnoses are considered to be 
most likely in the following order: SAH, ICH, IS, Other cerebrovascular disease, TIA. 






Figure 2. Different situations of forming an episode and classifying stroke subtype.  
A. Only one discharge with cerebrovascular disease, classified as ischemic stroke (IS), with 
start and end dates of episode those of the record. B. An acute hospital stay, followed by a 
rehabilitation stay. Classified as IS, ending at end of continuous hospital stay (end of 
sequalae). C. Two records on the same day, with different diagnoses. Episode classified as 
ICH, as this diagnosis is considered to be more likely to be correct. D. First an unclassified 
stroke diagnosis, directly followed by an ICH diagnosis. The latter is considered correct, and 
the date of stroke is the start date of unclassified stroke record. E. The first record is sequalae 
of stroke. The patients is likely to have a history of stroke, even if a new one may have 
developed. Excluded from PERFECT. F. A non-stroke diagnosis, followed by a stroke 
diagnosis. Classified as IS. Date of stroke is the beginning of IS record, not beginning of 
hospital stay with myocardial infarction. G. IS episode, with another diagnosis in-between and 
later followed again by an IS diagnosis. Not considered a recurrence. 
Lengths of stay (LOS) are counted for several aspects of the care:  
 
a) first hospital discharge entry = initial treating unit 
b) first episode, including acute care and rehabilitation, until discharged home or to a 
nursing home 
c) all other later hospital care within a year of stroke = re-hospitalizations 
d) total in-patient days within a year of stroke = b) + c) 
e) the LOS of care with a stroke primary diagnosis of all episodes included in d) 
I63 Ischemic stroke 
I61 ICH 
I69 Sequalae of stroke 
I64 Other CVD 
I25 Myocardial infarction 
I63 Ischemic stroke 
I61 ICH 
I63 Ischemic stroke 
I69 Sequalae of stroke 
I69 Sequalae of stroke 
I63 Ischemic stroke 
I63 Ischemic stroke 













4.4 Definitions of procedures, medications, and comorbidities 
Procedures are coded as part of the HILMO discharge record using the Nordic casemix 
center NCPS+ procedure codes (http://www.nordcase.org/eng/ncsp/), and some were 
included in the PERFECT database. Of interest in ischemic stroke were carotid 
endarterectomy (PAF*) and thrombolytic therapy (AAL10); in ICH, hematoma evacuation 
(AAD15 and AAB30); in SAH, aneurysm closure (AAC10 and AAL10); and in both SAH 
and ICH, procedures to control elevated CSF pressure (AAF*). 
 
Data on medication use was retrieved from the registry of prescription medication 
purchases of SII. The registry was scanned one year prior and one year post stroke for 
each patient, and a single entry was considered to signify that the patient had been 
prescribed that medication and did purchase it. Antithrombotics, antihypertensives, and 
statins were of primary focus, but also diabetes medications, antidepressants, and dementia 
medications were of interest. Of the antithrombotic medications, ASA is prescription-free, 
and thus its use cannot be followed. Also antiepileptic medications would have been of 
interest, but are used for such a variety of indications that conclusion on their use would 
have been difficult. The medications being evaluated are listed in Table 2. 
 
Table 2. Medication purchases being evaluated in the PERFECT Stroke project, and 
corresponding Anatomical Therapeutic Chemical Classification System (ATC) codes. 
Medication ATC-code 
clopidogrel B01AC04 




AT II antagonists C09C*-D* 
betablockers C07* 
calciumblockers C08*, C07FB*, C09BB* 
diuretics C03*, C07BB*, C09BA*, C09DA* 
insulin A10A* 
oral diabetes medication A10B* 










Several comorbidities, considered clinically relevant and with potential to influence stroke 
subtype, severity, and patient outcome, were included in the PERFECT Stroke database. 
Information on comorbidities was collected from several overlapping sources:  
 
1. Medication purchase data was evaluated one year prior to stroke, as explained 
above.  
2. SII Special reimbursement codes for chronic disease were evaluated for codes 
active at the time of the stroke. 
3. Previous hospital discharge register records were scanned for primary diagnoses 
from year 1987 onwards. 
The codes used for finding the comorbidities are listed in Table 3. If any of these methods 
suggested comorbidity, the patient was considered to have that comorbidity. 
Table 3. Comorbidities being evaluated in the PERFECT Stroke project, and the 
corresponding coding. 
Co-morbidity ICD-10 ICD-9 SRC ATC-code 
Hypertension I10*-I15* 40* 205 C03*, C07*†, C08*, C09* 
Coronary heart disease I20*-I25* 410*-414* 206 - 
Atrial fibrillation I48* 4273* 207 - 
Cardiac failure I50* 428* 201 - 
Peripheral artery 
disease I70* 440* - - 
Diabetes E10*-E14* 250* 103 A10A*, A10B* 
COPD and asthma J44*-J46* 4912*,496*,493* 203 R03* 
Alcoholism/drug abuse F10*-F19* 291*,304*, 305* - - 
Dementia F00*-F03*, G30* 290*,3310* 307 N06D* 
Depression F32*-F34* 2960*,2961*,2069* - N06A* 
Parkinson’s disease G20* 332* 110 N04B* 
Other mental disorder F20*-F31* 295*-298* except for 2960*,2961*,2069* 112,188 
N05A* except 
for N05AB04 & 
N05AB01 





L01* except for 
L01BA01 
ICD-10 = International classification of diseases Finnish version 10 (years 1996 onwards) 
ICD-9 = International classification of diseases Finnish version 9 (years 1986-1995) 
SRC = Social insurance institution (SII) special reimbursement code 
ATC =  Anatomical Therapeutic Chemical Classification System 
* = any ending of the code 






4.5 Stroke center classification 
Information on in-hospital processes is scarce in the hospital discharge register, and thus 
cannot be reliably evaluated on individual patient level, except for certain procedures 
mentioned earlier. To be able to evaluate the effect of differences in hospital resources and 
processes on patient outcome, an external data source had to be used. 
 
The Finnish Stroke and Dysphasia Association had organized an audit of acute stroke care 
in Finland in the year 2003, described in detail elsewhere (Roine et al. 2006). A re-audit 
was performed in year 2006 (Puumalainen et al. 2006). Based on these two audits, all 
Finnish hospitals were classified, according to the Brain Attack Coalition (BAC) criteria 
(Alberts et al. 2000; Alberts et al. 2005), as Comprehensive Stroke Centers (CSC), 
Primary Stroke Centers (PSC), or General Hospitals (GH). All the criteria had to be met in 
order to fulfill the CSC or PSC classification, as described in detail in Table 1 of study III. 
4.6 Estimation of costs 
For the purpose of this study, only direct healthcare costs were evaluated. A societal 
perspective was used, which includes the healthcare costs irrespective of payer; usually 
the health district for acute care; either health district of commune for early rehabilitation; 
and sometimes the SII or other insurance company for long-term rehabilitation. Also co-
payments by patients were included in the costs, which constitute on average 4% of public 
specialist care costs, 9% of general practice costs, 21% of nursing home costs, 31% of 
medication costs, and 75% of private medical services (Pekurinen et al. 2010). Altogether, 
co-payments by patients financed 19.4% of the Finnish healthcare in the year 2008 
(OECD 2010). Although a societal perspective was used, only direct healthcare costs were 
included, which leaves indirect costs, such as lost productivity, outside the scope of this 
paper. 
 
The methodology for estimating costs in the PERFECT project is generic for all the 
disease groups, not specific for stroke. The stroke project steering group was not involved 
in the development of the methodology in this respect, but this was rather done by a 
methodological group within CHESS. The methods presented are an extension and 
improvement of an earlier CHESS hospital Benchmarking methodology, which was fully 
hospital-based, and did not evaluate episodes of care. 
 
The costs in the PERFECT project were evaluated with different methodology for in-
patient care, outpatient visits, and medication purchases. 
 
To evaluate the costs of in-patient care, a costing database, based on national weighted 
diagnosis related group (DRG) daily costs and patient-level data on DRG days, was used. 
The optimal approach would have been to use detailed patient-level in-hospital cost data, 





costing systems implemented, and in any case there would have been differences in 
costing methodology between hospitals, which would have made the data incomparable. 
 
Therefore, a standard costing database was used, based on data from the Helsinki and 
Uusimaa Hospital District (HUS), which includes a population of 1.5 million inhabitants, 
30% of the Finnish population. HUS has a detailed sophisticated costing system with 
individual patient-level cost data on laboratory tests, imaging, procedures, outpatient 
visits, and ward-days incorporating all ward personnel costs, medications, and overheads. 
Using the HUS data for all patients treated for any reason, each patient care record was 
classified according to the Nordic DRG system, version 2001, in DRG categories, and 
mean costs for each category per days spent in that category were calculated. Day-surgery 
was grouped separately within DRG groups.  
 
In the next step, all the in-patient care for any reason in Finland in the year 2003, as 
retrieved from the HILMO database, was classified similarly to DRG groups. The relative 
costs per day of each HUS DRG category were then scaled to national data so that the 
relative cost weight of an average DRG category received a value of 1. Thus the relative 
costs between DRG groups were assumed to be equal in all parts of Finland. With these 
DRG costs, the national total costs of healthcare were annually distributed among the total 
number of national DRG days, to get annual cost per DRG day in each DRG group. To 
evaluate true costs per patient, these annual national DRG-specific daily costs were then 
applied to individual patient data: (Number of days spent in DRG A) x (National daily 
cost of DRG A for that year) + (Number of days spent in DRG B) x (National daily cost of 
DRG B for that year) etc. For long-term and psychiatric inpatient care, fixed national costs 
were used, taking nursing intensity into account. All costs were recalculated annually.  
 
Costs of outpatient visits in public hospitals were valued with similar methodology as in-
patient costs, again using HUS costing data, but now grouping visits not by DRG group, 
but by treating specialty and acuteness (emergency visit or scheduled visit). Again these 
visit costs were calculated annually, and used for the whole country. For private outpatient 
visits, costs were derived from the SII registers. For general practice (GP) visits, no 
national registry exists. Thus GP costs were not included in the PERFECT database, and 
neither were community outpatient nursing costs 
  
Costs for outpatient medications were derived from the SII registry of prescription 
medications, and thus are true patient-level costs. This registry only includes medications 
which require a prescription. Over-the-counter medications are relatively in-expensive, so 
their effect on costs would have been small. The registry does not include medications 
administered by hospitals or GPs, such as drug infusions, as these are included in the costs 







4.7 Outcome measures 
Several measures were used to evaluate patient outcome. The most concrete and clear cut 
outcome is mortality, which is easily measured using the data from the CDR. Mortality 
was evaluated at several time points, both short term, i.e. 1 month, to measure 
effectiveness of acute care; at 1 year, to measure the effectiveness of rehabilitation, 
follow-up, and secondary prevention; and long-term, up to a decade, to measure the long-
term effects of rehabilitation, secondary prevention, and changes in median survival of 
patients.  
 
In addition to mortality, a functional outcome evaluation in the surviving patients would 
have been welcome, such as the widely used mRS score. However, such scores are not 
nationally registered, so one has to settle for a surrogate outcome measure for functional 
outcome. Living status was used for this purpose. Whether a patient was living at home at 
various time points after stroke, and the number of days spent home within a year from 
stroke were evaluated. In addition to institutional care, independence among the patients 
living at home would have important to know, but again, this is not registered nationally. 
 
Mortality and need for institutional care mainly reflect the success of acute care and 
rehabilitation. In long term follow-up, also the success of secondary prevention is 
important and of interest. Recurrences were therefore evaluated. It is not possible to 
deduce possible recurrences or multiple strokes within the initial stroke in-hospital 
episode, as the stroke primary diagnosis could reflect either the initial stroke or a 
recurrence. Therefore, only new acute stroke hospitalizations were considered recurrences. 
In order to minimize the risk of incorrect coding, a new acute stroke episode was 
considered a recurrence only when: 
 
a) The initial stroke episode of continuous in-patient care had finished, i.e. the patient 
had been discharged home or to a nursing home AND 
b) Patient was admitted through the emergency room with a primary diagnosis of 
acute stroke AND 
c) The new episode lasted at least 3 days or lead to death before that     
4.8 Benchmarking 
An important aspect of the PERFECT Stroke project has been to compare providers and 
geographical areas with regard to performance, effectiveness, and costs. To make such 
comparisons meaningful, the patient case-mix have to be similar, which is usually not the 
case, or the differences in patient case-mix have to be adjusted for. 
 
As there are large differences in the age distribution and prior co-morbidities of patients 





differences. As adjustments cannot take all differences in case-mix into account, such as 
stroke severity which is not nationally registered, the patients for comparisons were 
chosen in a way to make them more alike. For benchmarking purposes, only ischemic 
stroke patients were compared, and the following patient groups were excluded: 
 
1. Patients younger than 18 years of age – the rare cases often treated in pediatrics 
2. Non-residents – tourists and visitors cannot be reliably followed up 
3. Residents of the Archipelago of Åland – the total population is small, less than 
30 000 people, and these patients are sometimes treated in Sweden 
4. Patients residing in a long-term institution before their stroke, defined as 90  days 
of continuous in-patient care prior to their stroke 
 
The benchmarking itself was performed by adjusting for age, sex, prior co-morbidities as 
defined before, and the use of warfarin or statin prior to stroke. These two medications 
were adjusted for separately, as their indication cannot always be deduced from register 
data. The medications and co-morbidities were chosen by the PERFECT Stroke steering 
group based on possible clinical relevancy. 
 
Annual reports of the benchmarking population, with both crude and adjusted figures for 
baseline demographics, LOS at various levels of care, procedures, medications prior and 
post stroke, costs, and outcome measures, have been produced. 
 
Two sets of annual reports are given. In the first set, all health districts are compared with 
each other, to evaluate geographical differences and the success of whole chains of 
recovery. In the second set, all hospitals with at least 50 benchmarking population patients 
in the year 2003 are compared with each other, to evaluate possible provider differences in 
mainly acute care. For hospital comparisons, when the patient was rapidly transferred 
between hospitals, the highest level of care within the first week of stroke (local hospital, 
regional hospital, or university hospital) was considered to have been responsible for the 
patient care. In the beginning of year 2007, two regional hospitals (Jorvi and Peijas) were 
organizationally joined with the Helsinki University Central Hospital (HUCH), and all of 
the patients were grouped under HUCH.   
 
The follow-up for the main outcome measures is 1 year, and the registries have to be 
checked, cleaned, and linked after the follow-up period. There is therefore currently a two-
year lag from patient care to reports. For study III, data was available for patients with 
their first-ever stroke between 1st January 1999 and 31st December 2006 with follow-up of 
all patients until 31st December 2007. For studies I, II, and IV, data was available for 
patients with their first-ever stroke between 1st Jan 1999 and 31st December 2007 with 
follow-up of all patients until 31st December 2008, and has since become available also for 
patients with their  first-ever stroke up to 31st December 2008 with follow-up of all 






4.9 Statistical methods 
Continuous data is presented as median with interquartile range, or mean with standard 
deviation. Categorical variables are presented as numbers and percentage of category total. 
Differences between multiple groups (study III) are analyzed with Kruskal-Wallis or 
analysis of variance methods where appropriate. In the annual reports, incidence of 
benchmarking ischemic stroke patients is reported as crude per 100 000 population, and as 
age and sex standardized to the national population of that year. For comparison of 
incidence in time, the data is age and sex standardized to a fixed year with the direct 
method.  
 
For benchmarking purposes in the annual reports, and in studies II, III, and IV, suitable 
regression models are used for adjustment of baseline imbalances. Logistic regression 
models are used for binary outcomes (mortality, institutional care, recurrence), and 
generalized linear models (GZLM) with gamma distribution and log link for continuous 
outcomes (LOS, costs, days spent home within a year of stroke). All the models used the 
same covariates which were forced in to the model: age, sex, all comorbidities, and use of 
warfarin and statin prior to stroke. For benchmarking purposes, with the model parameter 
estimates, an expected probability for each outcome was calculated for each patient. The 
observed outcomes of patients in a hospital or health district were compared to the 
expected outcomes of the same patients (observed/expected) (DeLong et al. 1997). This 
proportion was multiplied by 100 to derive an index where 100 was the national average 
for that outcome, and the index value for each outcome described how many percentages 
of the national average that district or hospital had achieved after adjustment for 
imbalances. The index values are reported with 95% confidence intervals, calculated as 
described elsewhere (Ash et al. 2003). 
 
For analysis of time trends in the care and outcome of patients of the whole country (study 
II), all first-ever IS, ICH, and SAH patients were included. The regression models were 
otherwise similar to the ones used in annual reports, but prior living status was adjusted 
for, as also previously institutionalized patients were included in the analysis. Year of 
stroke was introduced as a covariate to analyze possible differences over time. To test for 
difference in long-term outcome between patients of years 1999 and 2007, a Cox 
proportional hazards regression model was utilized with the same covariates. 
 
For analysis of hospital stroke center designation effect on patient outcome (studies II and 
III), similar logistic and Cox regression models were utilized, with hospital classification 
introduced to the model. As most stroke patients are in Finland are treated by neurologist, 
but also many by GPs or internal medicine specialist, the analysis was done separately for 
patients treated by neurology only (study II). To further test the independent effect of the 
treating specialty (study II), the same models were run with a dichotomous variable 
included: acute care by neurology vs. non-neurology in IS and ICH; or neurosurgery vs. 
non-neurosurgery in SAH.    






5.1 National stroke database (Study I) 
The PERFECT Stroke database includes 104 899 first-ever stroke patients for the years 
1999 to 2008, of whom 82 950 (79.1%) had IS, 14 267 (13.6%) ICH, and 7682 (7.3%) 
SAH as their first stroke (Table 4). Men and women had almost as many strokes, but men 
had their strokes a decade younger than the women. The age- and sex distribution of the 
patients for the whole 10-year period are shown in Table 5, and the data for the years 1999 
and 2008 graphically (Figure 3, Figure 4, Figure 5).  
 
Median age was 74, with interquartile range (IQR) of 63 to 81 years. The corresponding 
figures among IS patients were 75 (67-82) in 1999 and 76 (65-83) in 2008; among ICH 
patients 72 (61-79) and 72 (61-81); and among SAH patients 54 (44-67) and 57 (48-69) 
respectively. Of all patients, 6313 (6.0%) were living in an institution before their stroke. 
Table 4. Number of patients by stroke subtype, years 1999 – 2008 
  1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 
SAV 866 801 787 786 754 824 709 739 721 695 
ICH 1 449 1 410 1 406 1 408 1 439 1 389 1 451 1 419 1 415 1 481 
IS 8 390 8 387 8 570 8 172 8 178 8 418 8 069 8 172 8 213 8 381 
Total 10 705 10 598 10 763 10 366 10 371 10 631 10 229 10 330 10 349 10 557 
 
Table 5. Age- and sex distribution of stroke patients, years 1999 – 2008, with cumulative 
percentage for age-group total. 
 Age IS ICH SAH Total Stroke 
 
Male Female Male Female Male Female Male Female Cum.% 
0-24 116 125 93 46 81 61 290 232 0,5 % 
25-34 216 196 102 58 179 157 497 411 1,4 % 
35-44 837 513 285 137 537 518 1 659 1 168 4,1 % 
45-54 3 355 1 596 903 477 975 1 009 5 233 3 082 12,0 % 
55-64 7 854 3 681 1 657 812 820 994 10 331 5 487 27,1 % 
65-74 12 116 8 947 2 055 1 521 473 760 14 644 11 228 51,7 % 
75-84 11 479 17 528 1 795 2 613 254 586 13 528 20 727 84,4 % 
85-94 3 374 10 195 390 1 255 60 205 3 824 11 655 99,1 % 
95+ 131 691 14 54 3 10 148 755 100,0 % 






Figure 3. Age and sex distribution of IS patients, years 1999 (n=8390), 2008 (n=8381) 
Figure 4. Age and sex distribution of ICH patients, years 1999 (n=1449), 2008 (n=1481) 
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As the incidence of stroke is clearly and strongly age-dependent, and the population of 
Finland is rapidly ageing over the study period (Table 6), one would expect to see more 
stroke cases over time. This has not been the case, mainly due to decrease in stroke 
incidence in the oldest patients. The total age and sex adjusted incidence fell by 18% over 
the study period (Table 7), most of which was due to IS patients (Table 8).  
 







   Male Female Total  Male Female Total 
0-24 818 744 784 529 1 603 273  791 624 758 155 1 549 779 
25-34 337 911 324 102 662 013  346 247 328 244 674 491 
35-44 390 473 376 952 767 425  346 410 333 645 680 055 
45-54 418 501 409 510 828 011  381 504 378 146 759 650 
55-64 264 616 278 796 543 412  380 565 389 706 770 271 
65-74 190 450 245 333 435 783  218 156 254 691 472 847 
75-84 83 782 170 547 254 329  120 859 194 565 315 424 
85-94 17 955 55 793 73 748  25 213 72 459 97 672 
95+ 594 2 714 3 308  1 075 5 050 6 125 
Total 2 523 026 2 648 276 5 171 302  2 611 653 2 714 661 5 326 314 
 
 
Table 7. First-ever all stroke incidence in the PERFECT database per 100 000 population 
in Finland, years 1999 and 2008, according to age and sex.  
  1999  
 
 2008   
 
 Male Female Total 
 Male Female Total  Change 95% CI 
0-24              3                 2                 3                  3                 4              3    12 % -30     55% 
25-34            18               12               15                14               13            14    -9 % -36     18% 
35-44            49               35               42                44               33            39    -9 % -24     7% 
45-54          148               72             110              125               81          103    -6 % -16     3% 
55-64          365             174             267              306             159          232    -13 % -20     -7% 
65-74          826             530             659              617             397          498    -24 % -29     -20% 
75-84       1 559          1 258          1 357           1 224          1 007       1 090    -20 % -24     -15% 
85-94       2 066          1 981          2 001           1 690          1 699       1 696    -15 % -22     -9% 
95+       2 862          1 990          2 146           1 767          2 158       2 090    -3 % -33     25% 
Total          203             210             207              197             200          198    -4 % -7     -2% 
Total*              162             176          171    -18 % -20     -15% 
Change in total stroke incidence, with 95% confidence intervals (CI) calculated with the Newcombe-Wilson 
method without continuity correction (Newcombe 1998). 







Table 8. First-ever ischemic stroke incidence in the PERFECT database per 100 000 
population in Finland, years 1999 and 2008, according to age and sex.  
  1999  
 
 2008   
 
 Male Female Total 
 Male Female Total  Change 95% CI 
0-24              1                 1                 1                   2                 3                 2    69 % -5     199% 
25-34              5                 3                 4                   8                 7                 8    85 % 16     196  
35-44            21               10               16                 26               17               22    39 % 9     77  
45-54            93               37               65                 80               42               61    -7 % -18     6% 
55-64          274             115             192                233             105             168    -13 % -20     -5% 
65-74          679             417             532                511             327             412    -23 % -27     -18% 
75-84       1 312          1 071          1 150             1 053             843             924    -20 % -24     -15% 
85-94       1 838          1 789          1 801             1 448          1 450          1 450    -19 % -25     -13% 
95+       2 862          1 805          1 995             1 488          2 020          1 927    -3 % -28    30% 
Total          157             167             162                157             158             157    -3 % -6     0  
Total*     128 139 134 -17% -20     -15% 
Change in total stroke incidence, with 95% confidence intervals (CI) calculated with the Newcombe-Wilson 
method without continuity correction (Newcombe 1998). 
*Age and sex standardized with the direct method to the population of the year 1999. 
 
The prevalence of stroke survivors in Finland was estimated at 82 000 at the end of the 
year 2008, based on observational data of the patients with their stroke in the years 1999 
to 2007, 50 929 patients of whom were alive at that date, and extrapolation of the patients 
of years 1970 to 1998, as shown in Figure 6.  
Figure 6. Patients alive at end of 2008, by year of incident stroke. Observational PERFECT-
















Some comorbidities prior to stroke became more common (cancer, depression, 
hypertension, and COPD), and some less frequent (coronary heart disease and cardiac 
failure) (Table 9). All comorbidities were associated with outcome (Table 10).  
 
Of all stroke patients, 62% were treated in stroke centers (Table 2 of Study I), and of the 
IS patients, 6% received thrombolytic therapy and 49% a guideline combination of 
secondary preventive medications (Table 2 and discussion of Study I).  
 
Table 9. Prior co-morbidities in stroke patients of the years 1999 and 2008.  
  
IS ICH SAH 
1999 2008 1999 2008 1999 2008 
Hypertension 63 % 68 % ** 52 % 55 % 30 % 40 %** 
Coronary heart disease 29 % 26 % ** 18 % 18 % 8.2 % 8.1 % 
Atrial fibrillation 15 % 16 % 10 % 11 % 3.2 % 3.7 % 
Cardiac failure 18 % 11 % ** 12 % 7.1 % ** 2.5 % 2.6 % 
Periferal artery disease 4.5 % 3.7 % * 2.5 % 2.3 % 1.0 % 1.6 % 
Diabetes 19 % 19 % 11 % 14 % * 4.2 % 7.5 % * 
Chronic obstructive pulmonary disease 12 % 15 % ** 11 % 10 % 9.1 % 12 % * 
Cancer 8.2 % 13 % ** 8.4 % 11 % * 3.2 % 5.6 % * 
Depression 12 % 15 % ** 12 % 13 % 10 % 14 % * 
Dementia 2.8 % 7.3 % ** 2.6 % 8.9 % ** 0.5 % 2.0 % * 
Alcoholism 1.8 % 4.2 % ** 4.8 % 4.7 % 4.3 % 4.6 % 
Other mental disease 7.9 % 6.6 % ** 7.4 % 5.6 % 4.4 % 4.5 % 
Parkinsons's disease 3.1 % 4.9 % ** 3.6 % 3.2 % 2.7 % 2.7 % 








Table 10. Effect of comorbidities on 1-year case-fatality. 
 IS ICH SAH All stroke 
Age, per year 1.07 (1.07-1.08) 1.03 (1.03-1.04) 1.04 (1.04-1.04) 1.05 (1.04-1.05) 
Male sex 1.06 (1.02-1.11) 1.03 (0.95-1.11) 1.04 (0.92-1.16) 0.97 (0.94-1.01) 
Hypertension 1.15 (1.10-1.20) 1.15 (1.06-1.25) 1.25 (1.10-1.41) 1.05 (1.01-1.09) 
Coronary heart disease 1.18 (1.13-1.23) 1.22 (1.10-1.36) 1.26 (1.03-1.53) 1.12 (1.08-1.16) 
Atrial fibrillation 1.27 (1.21-1.34) 1.16 (1.01-1.34) 0.79 (0.58-1.07) 1.15 (1.10-1.20) 
Cardiac failure 1.64 (1.57-1.73) 1.41 (1.22-1.62) 1.35 (0.99-1.85) 1.60 (1.53-1.67) 
Periferal artery disease 1.88 (1.74-2.04) 2.27 (1.77-2.90) 1.06 (0.68-1.65) 1.72 (1.60-1.84) 
Diabetes 1.24 (1.18-1.30) 1.29 (1.15-1.45) 1.00 (0.79-1.26) 1.11 (1.07-1.16) 
COPD 1.07 (1.01-1.12) 0.96 (0.85-1.09) 0.93 (0.78-1.12) 1.00 (0.95-1.04) 
Cancer 1.47 (1.39-1.55) 1.84 (1.63-2.07) 1.41 (1.12-1.78) 1.52 (1.45-1.59) 
Depression 1.15 (1.09-1.22) 1.08 (0.96-1.21) 1.00 (0.83-1.22) 1.14 (1.09-1.20) 
Dementia 2.16 (2.01-2.32) 1.84 (1.55-2.19) 1.53 (0.95-2.46) 2.14 (2.00-2.28) 
Alcoholism 1.66 (1.47-1.86) 1.22 (1.02-1.47) 1.62 (1.25-2.11) 1.53 (1.39-1.67) 
Other mental disease 1.68 (1.57-1.80) 1.41 (1.21-1.64) 1.24 (0.96-1.61) 1.50 (1.42-1.59) 
Parkinsons's disease 1.09 (0.99-1.20) 1.17 (0.95-1.43) 1.21 (0.84-1.76) 1.10 (1.01-1.19) 
Prior warfarin use 1.13 (1.06-1.20) 1.47 (1.29-1.67) 1.40 (1.04-1.89) 1.27 (1.21-1.34) 
Prior statin use 0.65 (0.61-0.68) 0.70 (0.62-0.78) 0.93 (0.77-1.11) 0.64 (0.61-0.66) 

































5.2 Trends in stroke case-fatality (Study II) 
There has been a marked decrease in the overall 1-year case-fatality of IS patients from 
1999 (26.2%) to 2008 (21.6%), owing mostly to the decrease in very early deaths within 
28 days of stroke, 13.0% to 10.0% respectively. A similar trend was seen among ICH 
patients, with 1-year case-fatality dropping from 43.0 to 40.9%, stemming exclusively 
from decreased 28-day mortality (32.2% to 29.3%). Among SAH patients, no clear trend 
was seen (Figure 7).  


















The decrease in case-fatality has led to increased life-expectancy after stroke. After 
adjusting for patient characteristics, the median survival after IS has increased by 2 years, 
and after ICH by 1 year over the study period (Figure 4 of Study II).  
 
The proportion of patients treated at stroke centers and by neurologists increased steadily 
over the study period, and this centralization and specialization of care was associated 
with increased patient survival (Study II). After adjusting for patient case-mix, treatment 
by neurologists was associated with increased 1-year survival among IS (OR 1.77; 1.70-
1.84) and ICH-patients (OR 1.54; 1.40-1.69) when compared to treatment by any other 
specialty. Treatment by neurosurgeons was likewise associated with increased 1-year 






5.3 Stroke centers (Study III) 
The last audit of facilities and processes of hospitals treating stroke in Finland was 
performed in the year 2006. Thus the effect of stroke centers on patient outcome was 
analyzed in the patients of the years 1999 to 2006. Only ischemic stroke was analyzed in 
study III, and exclusions were done as in the annual PERFECT Stroke reports. The total 
number of patients in this analysis was 61 685. Of these patients, half were treated in 
general hospitals (GH, n = 30 891), 17% in primary stroke centers (PSC, n = 10 749), and 
32% in comprehensive stroke centers, (CSC, n = 20 045). In the year 2006, there were 7 
hospitals fulfilling PSC and 5 hospitals fulfilling CSC criteria in Finland.  
 
All-cause case-fatality within 1 year of stroke was 27.3 % in GHs, 19.1% in PSCs, and 
16.6% in CSCs. There were major imbalances in baseline characteristics of the patients 
treated in the various hospitals. After adjusting for these, the risk of death within 1 year of 
stroke in patients treated in GHs was 23.2% (95% CI 22.8–23.6%), in patients treated in 
PSCs 21.7% (20.9–22.5%), and in patients treated in CSCs 20.8% (20.2–21.5%). The 
number-needed-to-treat (NNT) to allow 1 more patient to live at home 1 year from stroke 
was 29 (23–38) for CSCs, 40 (28–68) for PSCs, and 32 (26-42) for stroke center combined 
when compared with GHs.  The difference between PSC and CSC was not statistically 
significant, NNT 100 (50– -1100). 
 
After publication of study III, concerns were raised whether the stroke center effect was 
due to treating specialty, not due to stroke center facilities. This was tested in study II, 
where the analysis was now restricted to patients treated by neurologists (69% of all IS 
patients) in either GH or a stroke center. The effect of stroke center care on 1-year case-
fatality was in this analysis smaller (OR 0.94; 0.89– 0.99; p=0.022) than in the whole 
population (OR 0.79; 0.76–0.82; p<0.001). Similarly, a smaller but still positive effect of 
stroke centers was seen when the analysis was restricted to patients treated in neurology, 
in the 1-year outcome of death or institutional care (OR 0.91; 0.88–0.96; p<0.001) vs. (OR 
0.76; 0.74–0.79; p<0.001) in the whole population. 
 
In study II, the effectiveness of stroke center treatment on ICH patient 1-year mortality 
among patients treated by neurologist (65% of all ICH patients) was also tested, and an 
effect just barely significant could be realized for patients treated in CSC (OR 0.90; 0.80–
1.00; p=0.05), but in the opposite direction among patients treated in PSCs (OR 1.13; 
1.00–1.29; p=0.06), when compared to GHs. Together, the stroke centers reduce the risk 
of death or institutional care after ICH only in a non-significant manner (0.92; 0.83–1.01; 







5.4 Costs of stroke (Study IV) 
Study IV was published in an American journal and the results were therefore reported in 
US dollars. Since then, the data of year 2008 has become available. The mean total 1-year 
cost of stroke patients in the year 2008, in 2008 values, was 20 446 € (median 10 875 €; 
IQR 5 041–25 218 €), 19 252 € (10 358 €; 5056–23 245 €) in IS patients, 23 873 € (12 739 
€; 4 352–32 641 €) in ICH patients, and 27 538 € (17 129 €; 6 366–36 230 €) in SAH 
patients. Costs in IS patients increased with age, but decreased in older ICH and SAH 
patients, mostly reflecting high case-fatality rates in the older hemorrhagic stroke patients 
(Table 11). 
 
The costs of stroke patients are primarily in-patient costs, while outpatient visits and 
medication costs form a minor portion. Absolute 1-year costs have increased during the 
last 10 years by 54% for total stroke, 48% for IS, 74% for ICH, and 84% for SAH 
patients. Cost of stroke care has increased more than healthcare costs in general, as during 
the same period the hospital cost index (www.stat.fi ) has increased by 35% only (Figure 
8). This development may have stopped, as stroke 1-year costs have increased from 2006 
to 2007 (3.0%) and 2007 to 2008 (1.6%) less than the healthcare cost index, 3.3% and 
5.6% respectively. 
 
Figure 8. Crude mean 1-year cost of stroke and the healthcare cost index, year 1999 = 100.  
The mean lifetime direct healthcare costs of a patient after stroke were estimated at 86 300 
€, or 88 900 € after IS, 87 600 € after ICH, and 55 400 € after SAH.  
 
The 1-year costs directly attributable to stroke, when the mean daily cost prior to stroke 
was subtracted from each day the patient survived, were 82% of total cost, or 79% in IS, 
89% in ICH, and 93% in SAH patients. Similarly, the lifetime costs directly attributable to 
stroke were 56 400 € (65% of all lifetime costs), or 55 900 € (63%) in IS, 65 700 € (75%) 


















The total cost of treating stroke patients in Finland is about 1.1 € Billion annually, 7% of 
total healthcare costs, or 0.6% of GDP (Study IV). 
Table 11. Total healthcare costs within 1 year of stroke by age and sex, year 2008, €. 
Male   00-24 25-34 35-44 45-54 55-64 65-74 75-84 85-94 95+ Total 
IS n 12 27 91 307 885 1 115 1 273 365 16 4 091 
 Mean 14 574 22 701 15 586 14 932 15 818 17 521 19 640 21 770 27 081 18 017 
 SD 11 696 41 675 23 719 21 248 21 043 20 983 23 952 24 065 49 068 22 727 
 Median 9 503 6 365 6 627 7 986 8 319 10 045 11 371 13 130 7 222 9 891 
 Percentile 25 5 624 3 357 4 595 4 324 4 402 4 910 5 419 5 621 5 576 4 891 
 Percentile 75 25 242 20 517 13 081 16 229 17 836 21 476 23 094 29 527 17 431 21 248 
ICH n 10 9 23 79 221 190 187 54 3 776 
 Mean 17 344 40 709 18 748 31 675 23 598 26 052 23 180 16 248 11 774 24 337 
 SD 14 759 40 372 19 618 37 046 31 251 30 380 30 784 20 506 15 962 30 726 
 Median 14 060 27 109 12 354 19 430 12 905 15 216 12 373 7 774 3 131 13 245 
 Percentile 25 2 653 12 370 4 826 6 270 4 431 5 483 3 730 2 132 1 998 4 560 
 Percentile 75 28 661 39 141 24 384 38 785 30 173 35 494 31 395 18 932 30 194 32 092 
SAV n 1 13 39 90 60 41 19 7 0 270 
 Mean 1 564 35 677 24 870 28 277 27 810 19 743 16 347 17 473  25 523 
 SD  36 864 31 842 30 514 27 943 21 574 16 993 35 575  28 697 
 Median 1 564 22 862 13 407 15 143 18 998 13 945 7 656 3 591  15 007 
 Percentile 25 1 564 15 028 5 296 8 381 7 932 5 057 5 430 460  6 193 
 Percentile 75 1 564 44 158 32 716 39 340 38 848 24 233 34 999 9 802  35 645 
Female 00-24 25-34 35-44 45-54 55-64 65-74 75-84 85-94 95+ Total 
IS n 19 24 57 157 408 832 1640 1051 102 4290 
 Mean 37126 17531 15608 15129 15420 18361 21977 22465 19922 20430 
 SD 96228 20863 16511 18942 20179 24439 28579 25341 27556 26592 
 Median 9332 7723 7677 7234 8365 9239 12239 13279 9702 10858 
 Percentile 25 4527 6645 4585 4025 4183 4771 5745 5977 5517 5259 
 Percentile 75 15307 23773 20531 18055 16292 22742 27553 29984 24111 25674 
ICH n 4 9 7 49 98 119 257 156 6 705 
 Mean 29897 28439 29956 22191 24439 25928 24631 18623 13694 23363 
 SD 28365 39342 33705 21294 31555 29858 31457 21876 14411 28699 
 Median 27455 10127 18349 17515 13445 12739 12261 9338 7979 12013 
 Percentile 25 6414 8807 4860 4138 4334 5015 4654 1865 1672 4061 
 Percentile 75 53380 19736 73017 30246 34051 40467 31573 27417 30681 33606 
SAV n 5 11 47 101 113 60 63 24 1 425 
 Mean 15145 17810 21276 32736 31233 32872 28038 16656 1752 28818 
 SD 13561 14725 18288 37091 33819 34008 40089 19982  33417 
 Median 18845 17129 15583 20070 20639 22662 16072 8838 1752 18037 
 Percentile 25 2734 6031 8616 8989 8618 7247 4431 2905 1752 6842 








In this study, a national stroke database was created using linkage of existing 
administrative registries. This method does not require extra data collection or input, and 
is therefore inexpensive and easy to maintain over long periods of time. Data for the first 
10 years show improvements in care of patients revealed by increased survival and less 
institutional care after stroke. Specialized and centralized care is associated with this 
improvement, and the effectiveness of stroke center care was shown for the first time 
anywhere in the world, with nationwide data for the whole population.  
 
The life-time direct healthcare costs of stroke patients are high, on average ~86 000 € from 
stroke until death, but a third of these are attributable to other concomitant diseases. The 
prevalence of stroke in Finland is about 82 000, 1.5% of national population, and these 
patients incur an annual healthcare cost of about 1.1 Billion €, 0.6% of the national GDP.  
 
Only 62% of stroke patients have been treated in stroke centers, which is four times higher 
than in Europe in general (Leys et al. 2007a), but still not satisfactory. Of IS patients, only 
6% received thrombolytic therapy and only 49% a combination of secondary preventive 
medications as suggested by national guidelines. Treatment of stroke is demanding and 
requires know-how and motivation. There is much room for improvement, and such 
improvements could have national economic impact. 
6.1 Main results in light of existing literature  
National stroke databases 
Several previous national stroke databases exist. These have been reviewed, compared 
with the PERFECT Stroke, and published earlier (Table 3 of Study I).  
 
The first and most comprehensive is the Swedish RIKS Stroke, with prospective 
registration of patients since 1994 (Stegmayr et al. 1999; Asplund et al. 2003; Appelros et 
al. 2007), about 80% of national patients registered, with extensive follow-up including a 
functional outcome measure at 3 months (Eriksson et al. 2007). Many of the elements 
registered in RIKS Stroke are identical to PERFECT Stroke: Prior place of living; 
comorbidities; medications before and after stroke; LOS and episode of care data; 
diagnosis; and in-hospital mortality. In addition, RIKS Stroke includes data on functional 
status (home-help, mobility, toilet visits, and dressing) before and after stroke; smoking 
status; information on whether a CT, MRI, or ultrasound was performed; information on 
complications; patient satisfaction; and most importantly, level of consciousness and 
NIHSS on arrival (Riks-Stroke Collaboration 2011). Thrombolytic therapy is included in 
the PERFECT database as a simple yes/no parameter, with some more detail in the RIKS 
Stroke, but to be really able to analyze this special therapy, more detail is needed, such as 





Although long-term follow-up and medication use data is not included in the RIKS Stroke 
registry, for research purposes it is possible to link this data (Eriksson et al. 2008; Asberg 
et al. 2010) in a similar fashion as has been done with PERFECT. Thus RIKS Stroke is a 
model example of a national stroke registry. 
 
A second database with full nationwide coverage is the Scottish Stroke Care Audit 
(SSCA, available at www.strokeaudit.scot.nhs.uk), which, just like PERFECT and RIKS 
Stroke, has been mainly hospital-based, and due to a large portion of patients treated as 
outpatients in Scotland, includes about 60% of national patients (Dennis et al. 2009). 
However, stroke clinics are currently also registering patients, likely to increase the 
coverage. The national reports are excellent in illustrating differences among providers 
and pinpointing improvement areas for clinical practice (Dennis et al. 2010). Long-term 
follow-up is not included in the SSCA and register linkage is more difficult to achieve in 
Scotland than in Sweden or Finland.  
 
In the USA there are two national projects for registering stroke patients, namely the Paul 
Coverdell National Acute Stroke registry (George et al. 2009), and the Get With The 
Guidelines (GWTG) registry run by American Heart Association (AHA) (LaBresh et al. 
2008). The former has been less popular and slower to spread nationwide, with 56,969 
patients registered from 2005 to 2007 and only few scientific publications on these. The 
latter has registered 1 million patients between 2003 and 2009 (Fonarow et al. 2010) and 
participation has been shown to improve patient outcome (Schwamm et al. 2009).  
 
Change in incidence 
PERFECT Stroke is not a true incidence study, with only hospital-based patient 
catchment. If the PERFECT data is used as a surrogate for incidence, the age-standardized 
decline in stroke incidence, reported at 2.0% annually over the years 1982 to 1998, has 
continued at a similar rate since, 1.8% annually over the years 1999 to 2008 (Table 7). In 
the younger IS patients below 45 year of age, this could not be seen (Table 8), with a 
slight increase instead, but the total numbers of these young patients were very small, only 
4% of all patients (Table 5, Figure 3). The total age and sex standardized incidence fell by 
18% (95% CI 15% to 20%) from 1999 to 2008. The positive trend reported since 1972 
(Tuomilehto et al. 1993; Numminen et al. 1996; Sivenius et al. 2004; Pajunen et al. 2005) 
continues. 
 
Stroke incidence has been studied in several studies over the last decades. When the 
PERFECT data is compared to these, the incidence rates are lower (Figure 9). This is 
natural, as patients who died before hospital admission, were treated as outpatients, or had 
an undetermined stroke were excluded from PERFECT. The CVDR database (Laatikainen 
et al. 2004) uses similar methodology and the same primary data sources as the PERFECT 
Stroke study, but there are significant difference in total numbers of annual patients 
(around 13 500 and 10 500 respectively). This is explained by different methodology. The 
CVDR registry contains non-traumatic epidural and subdural hematomas, which are 






the two strokes, which are not true first-ever strokes, and the cases of stroke which are 
fatal before hospitalization, which are true first-ever cases. The PERFECT database does 
not contain epidural or subdural hemorrhage patients, or patients with any previous stroke, 
checked for since 1987, but it does not either contain the true first-ever cases which were 
fatal before hospital admission. Also other differences exist. On the other hand the 
PERFECT database contain venous IS, usually considered stroke, and the diagnoses of 
stroke syndromes of the ICD-10 code G46, neither of which are included in the CVDR. 
Neither database contains the non-fatal stroke treated totally as outpatients. The true total 
number of annual incident stroke cases in Finland is likely to be somewhere in between 
the 10 500 of the PERFECT database, and the 13 500 of the CVDR database.   
 
Figure 9. Finnish stroke incidence in men (top panel) and women (bottom panel) by age, 
percentage of population. PK, EK, and FHA studies did not separate the 85+ age-group.           
Abbreviations: PK, Pohjois-Karjala; EK, Espoo-Kauniainen; KUO, Kuopio; TKU, Turku; 
JLÄ, Jyväskylä; FHA, Finnish Heart Association; CVDR, Cardiovascular Disease Registry.                             






























Stroke prevalence has been estimated at 41 000 (0.8% of population) 20 years ago 
(Rissanen 1992; Kaste et al. 2006), 60 000 (1.2% of population) 10 years ago (Aromaa 
and Koskinen 2004), and at 82 000 (1.5% of population) currently (Study I), which is a 
logical continuum with decreasing case-fatality. 
 
Comorbidities 
Comorbidities were common (Table 9), and their occurrence in the first-ever stroke 
patients were judged to be believable. All the comorbidities that the PERFECT Stroke 
steering group thought might influence patient outcome, did influence it (Table 10). Statin 
therapy prior to stroke was associated with decreased mortality, as has been shown before 
(Elkind et al. 2005; Reeves et al. 2008). 
 
Stroke centers 
Stroke unit effectiveness has been proven in numerous studies, but these units were 
defined in very broad terms (Stroke Unit Trialists' Collaboration 2007). More strict, 
detailed, and intensive stroke center designation criteria have been available for a decade, 
but no effect of stroke center care on patient outcome has been shown before Study III. 
Our results have since been replicated in New York (Xian et al. 2011), where in a 
population of 30 947 stroke patients, a 3.0% (95% CI 1.5-4.4%) decrease in 1-year 
mortality was shown after adjustment for, in addition to age, sex, and comorbidities, also 
race, insurance status, rural status, hospital teaching status, and size. The crude 1-year 
mortality was 22.3% in stroke centers, and 26.0% in non-designated centers. This study 
did not analyze PSC and CSC individually, but their NNT to prevent one death at one year 
of 33 (95% CI 23-67) was little lower, but in the same range as ours, 42 (32-60) for CSC, 
and 67 (42-172) for PSC, which combined for stroke centers equals 48 (36-70). This could 
mean that in Finland the difference between hospitals could be lower, and the level of care 
in general hospitals could be higher than in New York. 
 
While the effectiveness of stroke centers may have been expected, the results on ICH 
patient outcome were less intuitive. ICH patients were included in stroke unit trials, which 
altogether were positive, but no effect on ICH patients alone has been reported in those 
trials (Stroke Unit Trialists' Collaboration 2007). In Study II, a barely positive effect was 
seen for patients treated in comprehensive stroke centers, i.e. the five university hospitals 
in Finland, but not for PCS patients. Either a PSC standalone stroke unit, without the 
neurosurgical possibilities associated with CSC, is not enough for ICH patients, or there 




Treatment of IS and ICH patients in departments of neurology was superior to treatment 
by any other specialty in increasing 1-year survival, after adjustment for patient case-mix 
(Study II). The results are in concordance with a previous randomized trial performed in 
Finland in the 1980’s, where treatment by neurologists as compared to internal medicine 






patients treated at a department of neurosurgery fared better than those treated at any other 
specialty has not been studied before in Finland. 
 
Cost 
No previous cost study on stroke has been performed with individual patient data on a 
population level of a whole nation (Luengo-Fernandez et al. 2009). A mean 1-year cost of 
patients who had their first stroke in Finland in the year 2008 were shown to be 20 400 €, 
and the lifetime costs were estimated to be 86 300 € (Study IV). The lifetime cost are 
somewhat higher than has been previously reported in Finland and elsewhere, when all 
studies are converted to year 2008 value with each country’s consumer price index 
(available at http://stats.oecd.org)  and then to Euros with the exchange rate of 1.47 US$/€ 
(Table 12). The difference could be partly explained by increased survival of patients, as 
patient survival was a strong driver of total costs (Table of Study IV).  











(Taylor et al. 1996) 1990 5% 49 300 € 37 000 € 68 400 € 49 300 € 
 
Sweden 
(Terént et al. 1994) 
 
1983-1984 5% - - - 69 300 € 
Finland 
(Kaste et al. 1998) 1985-1989 5%    54 000 € 
 
Netherlands 
(Bergman et al. 1995) 
 
1991 0% 42 900 € 26 000 € - 40 900 € 
Australia 
(Dewey et al. 2003) 1996-1997 5% 29 900 € 52 300 € - 31 700 € 
 
Australia 
(Cadilhac et al. 2009) 
 









2003 5% 88 900 € 55 900 € 
87 600 € 
65 700 € 
55 400 € 
43 800 € 
86 300 € 
56 400 € 
All costs in 2008 values with corresponding consumer price indices, and Euros with rate 1.47 $/€. 
 
The total annual direct healthcare costs of all stroke survivors, 1.1 Billion €, equals about 
7% of all healthcare expenditure in Finland. This estimate is slightly higher than the 
earlier estimate based on 1980’s data from the Jyväskylä region, 6.1% (Fogelholm et al. 
2001). The costs of treating stroke patients have increased more than healthcare costs in 





increased survival automatically increases costs, as the dead patients are the least 
expensive (Study IV). Second, survival after ICH has increased, but unfortunately many of 
the survivors end up in institutional care, and are not able to return home (Study II). 
Stroke patients in long-term institutional care are the most expensive, costing about 






6.2 Study limitations 
Despite its name, this database is far from perfect. The registers which supply the data also 
limit what can be utilized. Only those data elements which are nationally registered could 
be included. Also, the PERFECT Stroke database may contain some patients who did not 
truly have an acute stroke, may have missed some patients who did have a stroke, and 
certainly does lack data on many critical aspects of stroke process, patient care, costs, and 
outcome. The two major limitations of the present study are missing data on stroke 
baseline severity, and functional outcome at one year. 
 
Specificity for including only stroke patients 
The information that can be derived from the data is only as good as the quality of the 
data. The quality of the hospital discharge register and the causes of death register with 
regard to stroke have been evaluated in three studies (Leppälä et al. 1999b; Mähönen et 
al. 2000; Tolonen et al. 2007). The first study, during both ICD-8 and ICD-9 coding, 
included 546 middle-aged men from an alphatocopherol and beta-carotein trial over the 
years 1985 to 1992, where a CT, MRI, lumbar puncture, surgery, or autopsy was 
performed in 86% of stroke patients. Of stroke diagnoses in the HILMO, 90% were truly 
strokes, a further 3% were TIA or other cerebrovascular disease, and in 7% a 
cerebrovascular diagnosis could not be confirmed (Leppälä et al. 1999b).  
 
The second study compared the HILMO and CDR with the FINMONICA Stroke registry 
over the years 1983 to 1994, and reported a 90% sensitivity and specificity of stroke 
diagnoses, but the paper is somewhat unclear on the methodology, does not report HILMO 
values separately from CDR values, and is thus difficult to interpret (Mähönen et al. 
2000). At that time, the validity of the HILMO diagnoses were higher than in Sweden, 
where the specificity of stroke diagnoses in the hospital discharge were less than 70% 
(Stegmayr and Asplund 1992). 
 
The most recent and relevant validation study was performed over the years 1993 to 1998, 
and thus, since 1996, included also the ICD-10 version stroke classification (Tolonen et al. 
2007). The HILMO and CDR were compared to the FINSTROKE registry, and unlike the 
two previous validation studies, had no upper age limit. Of all first-ever acute stroke 
diagnoses in the administrative registries, as used in the PERFECT Stroke database (I60 
SAH, I61 ICH, and I63 IS, n=3061), 93% were acute stroke (n=2838), 1% were old 
stroke, and 6% (n=182) were “non-stroke”. Later in the article they report, that 17% of the 
patients referred to as “non-stroke”, actually were acute stroke patients, just missed by 
FINSTROKE. Based on this data, the stroke diagnosis should be valid in 94% of cases, 
and a majority of the rest of the patients are probably TIA-patients. As TIA vs. stroke 
diagnostic criteria are evolving (FINSTROKE did not register TIA-patients, and used the 
time-based 24h criteria instead of a tissue-based criteria), the specificity of 94% may be an 
underestimation. Still, up to 6% of the patients included in the PERFECT database may 







Sensitivity for including all stroke patients 
In the same article, using FINSTROKE as the golden standard, Tolonen and colleagues 
report that only 2% of stroke patients in Finland were treated outside of hospitals. This 
tradition of treating all stroke cases as in-patients has been strong in Finland even during 
the first population-based incidence studies in early 1970’s, with 89% hospitalization rate 
reported by Aho (Aho and Fogelholm 1974), increasing to 95% in the late 1970’s (Kotila 
1986), and later in the 1980’s further to 95-97% (Mähönen et al. 2000). The hospital 
discharge register is therefore likely to include almost all stroke patients. However, many 
of the acute stroke patients are not coded as acute stroke, but rather by some other 
diagnosis, such as TIA, or a stroke syndrome (ICD-10 code G46). The sensitivity to catch 
all stroke patients with the ICD-10 codes I60, I61, and I63 was only 86% when compared 
to FINSTROKE (Tolonen et al. 2007). With the G46 codes it is therefore likely that about 
90% of all Finnish stroke patients are included in the PERFECT Stroke registry, missing 
outpatients, deaths before hospitalization, and incorrect coding.  
 
Insufficient coding of complications and procedures 
The PERFECT Stroke database does contain data on complications, but these are based on 
entering secondary diagnoses into HILMO, which, like the primary diagnosis, are not 
compulsory, and where coding activity varies between hospitals. The data has been judged 
unreliable by the steering group, and is not included in the annual reports. Complications 
are not insignificant, as they may deprive stroke patients on average two year of life (Hong 
et al. 2010).  
 
When compared to the SITS registry of thrombolytic therapies for stroke (Wahlgren et al. 
2007), where Finland had the highest rates of thrombolytic therapies per population 
among European countries, the coding of thrombolytic therapy in HILMO has been 
judged poor (Study I). This is possibly due to the procedure being still relatively new, not 
being compensated in all hospital districts, but also because neurology is a conservative 
specialty and is not used to coding procedures. Surgeons are used to coding a procedure 
for almost every patient, and accordingly the rates of carotid endarterectomy have been 
evaluated as reliable. 
 
Missing data elements 
The most important limitation of the PERFECT Stroke database is the missing data on 
stroke severity. In an extensively detailed local thrombolysis register (Meretoja et al. 
2010b), stroke severity was a more important determinant of patient 3-month outcome 
than age, sex, and all comorbidities put together (unpublished data). In this aspect, 
conventional stroke registries are superior. On the other hand, measuring stroke severity 
reliably requires training and certification of physicians, is not quick or easy even in 
experienced centers, is not comprehensively registered even in the most established 
national stroke register in Sweden, and is likely to form a selection bias when only stroke-
oriented centers do register this. In Finland, we have considered the aspect of trying to 






of the NIHSS (Lyden et al. 1994), and we do believe the project would quite likely fail. A 
more simple evaluation of stroke severity has been implemented and validated in 
Scotland, and may be one future option (Weir and Dennis 2001; Weir et al. 2003). 
 
In addition to stroke severity, a major drawback of this database is the lack of information 
on in-hospital processes, which could be quite useful in quality improvement, such as: 
  
 How many patients were imaged with CT / MRI on admission and during hospital 
stay? 
 How many IS patients received ASA within 24 h of admission? 
 How many patients received evaluation by occupational / speech / physiotherapist / 
neuropsychologist, and early rehabilitation? 
 How many patients were given advice on lifestyle modification? 
 
Information on ASA use after stroke would be useful, although the national guidelines 
suggest this use in combination with dipyridamole. Dipyridamole use can be currently 
tracked, as can be the use of clopidogrel and warfarin. 
 
Functional outcome measured by the mRS at 3 months after stroke has become the golden 
standard of outcomes in stroke trials. Evaluating for this in all stroke patients is not easy to 
accomplish. To do this reliably asks for training and certification of the assessor. A 
validated functional outcome based mainly on self-reporting has been accomplished in the 
Swedish national registry (Eriksson et al. 2007; Eriksson et al. 2008), and is therefore 
feasible. With PERFECT Stroke, only mortality and institutional care can be measured at 
three months. Among other details registered in existing national registries, but missing in 
the present one are: smoking status, level of consciousness at arrival, complications 
registered prospectively, and patient satisfaction. Recurrences can be evaluated with 
PERFECT data, but new strokes are known to be less well coded than first-ever strokes, 
could be subject to error, and must be validated. Furthermore, depression and cognitive 
decline after the first-ever stroke can only be evaluated indirectly, based on the 
medications bought by the patient. 
 
Cost data was missing for public general practice outpatient visits, home modifications, 
outpatient nursing, and other community help of patients living at home. 
 
Sources of error in the models 
Modeling was used to analyze the independent effect of stroke centers and treating 
specialty on patient outcome. Such models may be erroneous when very many variables 
are included at random, a situation called overmodeling. Overmodeling is a problem in 
small series, but with the numbers involved in the present study in not a real risk. Using 
the rule of 1 per 10, meaning that for each 10 outcomes, 1 factor can be considered for the 
model, we could have included hundreds of variables. Multicollinearity was not an issue 





independent of each other and, in the case of continuous variables, normally distributed. 
Age was the only continuous variable in the logistic models, while not quite normally 
distributed, still close to it (Figure 10). 
 
Figure 10. Distribution of age in ischemic stroke patients. 
For estimates of prevalence, future lifetime costs, and national total costs, extrapolations 
had to be made. For future costs, current case-fatality rate was assumed, and the steady 
development of costs over the years 2 to 5 after stroke, as shown in Figure 4 of Study IV, 
was assumed to continue. For prevalence, we extrapolated the trends in first year case-
fatality rates observed over years 1999 to 2007 (28.6% to 24.9%, thus decrease of 0.56% 
per year) backwards to year 1970. This implied a 1-year case-fatality of 34% in 1990 and 
39% in 1980. The extrapolation based totally on PERFECT data could be correct, as 
Mervi Kotila reported a 1-year case-fatality rate of 39.4% in the years 1978-1980 (Kotila 
1986), and Heikki Numminen a 1-year case-fatality rate of 34.1 % in the years 1989-1991 
(Numminen et al. 1996). Likewise, the annual case-fatality, observed to be stable annually 
after first year since stroke at around 8% in patients of 1999 and 7% in patients of 2006, 
was extrapolated to be around 11% in the patients of 1980. No Finnish comparison data 
for this later extrapolation exists.  
  
Delay in producing annual reports 
The PERFECT Stroke study has looked at most of its outcome measures with 1-year 
follow-up. This means that it takes a full year waiting for outcomes, more than half a year 
for the mortality outcomes to be fully registered thereafter (Statistics Finland personnel, 
personal communication) due to possible autopsies and delays in death certificates, and a 
few more months for the registers to be linked and the reports to be published. Therefore, 
the reports for year 2008 patients are produced a full 2 years after end of 2008. This is 
considered as a too long delay to measure changes in clinical practice when one wants to 

















In addition to the limitations mentioned above, in this study there are obvious strengths 
also. A lot of information has been gathered on stroke in Finland. With more than 10 000 
patients registered annually, for over 10 years, and using uniform methods, clear trends in 
treatment and outcome of patients could be seen. The large numbers reduced the error in 
these estimates. With full nationwide coverage, selection bias could be reduced, which is 
otherwise inherent in stroke registries with voluntary participation, usually over-
presenting centers with special interest and expertise in stroke care. A second strength of 
the registry is in the comprehensive long-term follow-up. Follow-up for case-fatality was 
100%, as all national deaths were included, and also deaths occurring outside of Finland 
are registered. For institutional care it is possible that a few patients could have moved 
abroad, and were living in institutional care there, which would not be registered in 
PERFECT Stroke. However, it is unlikely that severely affected patients would emigrate, 
and according to Statistics Finland (www.stat.fi) emigration in the elderly is rare 
altogether, less than 0.05% annually in the over 70-year olds, so follow-up for institutional 
care is likely to be better than 99.9%. Full nationwide coverage and long-term follow-up 
are unique to this study among national registries (Table 3 of Study I), although 






6.3 Implications for practice and future research 
The PERFECT Stroke database offers a wealth of data for research with over 100 000 
patients, full nationwide coverage, 100% follow-up for institutional care and mortality, 
and more than 10 years of follow-up. In addition to reports for benchmarking and quality 
improvement, the initial purpose of the database, also research on aspects of stroke that 
could be nationally and internationally interesting can be done. 
 
A paper on treatment practices in secondary prevention is under preparation, although not 
quite novel (Asberg et al. 2010; Menon et al. 2010). Also a deeper analysis of long-term 
costs in special patient groups, and an evaluation of indirect costs currently incurred by 
stroke in Finland could be meaningful to perform. The material is also especially useful 
for cost-effectiveness analyses, with cost and outcome data from the same patients, thus 
avoiding selection bias and the problem of multiple possible data sources involved in most 
cost-effectiveness analyses (Earnshaw et al. 2009; Guilhaume et al. 2010). An analysis of 
cost-effectiveness of secondary preventive medications has been performed, but not yet 
published (Meretoja 2009; Meretoja et al. 2009). Publication of the cost-effectiveness of 
the current concept of stroke centers could be analyzed and reported in detail, in order to 
promote a higher access to stroke care in Finland and around the world. 
 
Another branch of future research will be in international comparisons, with the extension 
of the methodology to other countries, where high quality administrative registries exists, 
with a common identifier, and no such legal obstacles which cannot be overcome. Such a 
project is already underway, coordinated by CHESS of THL, chaired by Unto Häkkinen. 
EUROHOPE (European Health Care Outcomes, Performance and Efficiency) is an EU-
funded project in seven European countries, namely Finland, Sweden, Norway, the 
Netherlands, Hungary, Italy, and Scotland, which will analyze utilizing administrative 
databases, among other disease, also stroke. The first results are expected to be available 
in the year 2012. 
 
Still, it is the original purpose of this study that needs the most urgent attention. Large 
scale registries of vascular disease are generally believed to lead the way towards higher 
quality and lower costs in healthcare systems (Ryan 2010), although making hospital 
performance data public may not automatically lead to corrective measures and 
improvements in performance, as was shown in the Canadian EFFECT study on cardiac 
care (Tu et al. 2009). The annual reports of PERFECT Stroke, which currently are large 
sets of raw tables published on a website, should be made more user-friendly to hospital 
administration and decision makers. Graphical presentation of the data, combined with a 
commentary, is a first priority. To be more effective, actually implement change, and truly 
improve quality, specific quality indicators, such as the proportion of patients treated in 
stroke centers, with thrombolytic therapy, and with secondary prevention according to 
national guidelines, should be prioritized, set target levels for, and widely communicated. 
The reports should be made available faster. These are specific challenges for the 







Also the PERFECT Stroke database could be improved. For epidemiological purposes, 
inclusion of patients who died before admission to hospitals, as retrieved from the CDR, 
could be useful, although there is little that can be done in the healthcare system for these 
patients. Still, the size of this group may partly reflect the success or failure of primary 
prevention. For health system research, burden to society, and to simply count the number 
of bed-days stroke patients consume annually, also recurrent cases could be included in 
the registry. Some sort of measures for stroke severity and functional recovery would be 
on the top of the wish list, but difficult to collect in a systematic way for the whole 
country. Complications and thrombolytic therapies should be coded more stringently, 
which could be promoted with educational campaigns. 
 
Implications of the current study on practice are clear. Stroke patients should be treated 
only in stroke centers and with guideline secondary preventive medications. This is not 
currently the case in Finland or elsewhere and something should be done. The 
responsibility lays with the ~20 chief physicians of the neurology departments in our 
country to convince the administration and political decision makers, secure the resources, 
and make sure all patients are treated in adequately equipped units specialized in the care 
of stroke patients. This will save lives and prevent patients from ending up in institutional 
care which is truly expensive. Even if the initial hospital costs may increase with stroke 
center care, the total costs only do very little, while the survival of stroke patients and the 







7 SUMMARY AND CONCLUSIONS 
To conclude, the PERFECT study has succeeded in forming a nationwide stroke database 
in Finland. With ~95% specificity and ~90% sensitivity for including all national stroke 
patients, 100% follow-up, and many meaningful measures on stroke care and outcome, the 
database should serve both clinicians and managers in the planning, implementation, 
evaluation, and improvement of care for stroke patients in Finland. 
 
In this study, a decline in stroke incidence, case-fatality, and mortality over the years 1999 
to 2008 were observed, continuing the trends seen since the 1970’s in Finland. A natural 
explanation is from more patients being treated in evidence-bases specialized stroke 
facilities and with guideline acute and secondary preventive medications. The success of 
primary prevention, steady improvement in the treatment of risk factors of stroke in the 
population, is likely to be as important. 
 
Evidence for benefit from organized care of stroke patients has been around for twenty 
something year, but the trials were done in settings very different from current stroke 
centers. In this study it was shown for the first time that patients treated in state-of-the-art 
stroke centers fulfilling stringent quality criteria are more likely to be alive and avoid 
institutional care than patients treated elsewhere. These results suggest that stroke patients 
should be treated in sufficiently specialized and well-equipped centers, a level usually 
attained and attainable only by large hospitals. 
 
The direct healthcare costs of individual stroke patients are significant, being on average 
~20 000 € over the first year since stroke, and on average ~85 000 € over the whole 
remaining life-time after stroke. The expected survival of stroke patients is increasing, 
which will in the future further increase the lifetime costs of stroke patients, and the total 
share of stroke patients of the national healthcare expenditure, which is currently 7%, 
although only two thirds of these costs are directly related to the stroke. 
 
While the trends in the quality of care and outcome of stroke patients in Finland have been 
positive, there is still much room for improvement, and by no means can we be satisfied 
with the current state. One third of stroke patients do not currently gain access to stroke 
centers, either due to geographical reasons, or due to local policies. This is unacceptable. 
Patients living in an institution before their stroke are unlikely to gain independence 
afterwards, but they represented only 6% of the patients in the present study. Those living 
at home may continue to do so if given a proper change at effective acute care and 
rehabilitation. Here we need to see a change in Finland. A second area in need of major 
improvement is the coverage and completeness of secondary prevention. Systems to 
continuously monitor success in risk factor control after stroke are missing, although 
national attempts have been made. Presently, we can only evaluate the purchases of 
medications after stroke, which are inadequate in half of ischemic stroke survivors. This 







Most of the data presented in this study has relevance in Finland. There are two messages 
for the international audience also. 1.) Modern stroke centers with an intensive and fully 
equipped service are effective, and should be made available for all stroke patients. 2.) It is 
possible, in a suitable setting with high-quality administrative registries and a common 
identifier, to avoid the huge workload and associated costs of setting up and hand-
collecting the data of a conventional stroke registry, and still acquire a fairly 
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